


























































































































































































































































































































































Multicellular organisms are constantly exposed to a variety of different microbes. To keep their 
integrity and to cope with potentially harmful pathogens, vertebrates have evolved a rapidly re-
sponding innate immune system as well as a less rapid responding adaptive immune system. Both 
immune responses are triggered by different immune receptors, which are either germline-
encoded to confer innate immunity or are assembled by complex somatic gene-rearrangements to 
assign adaptive immunity (Iwasaki and Medzhitov, 2010). The receptors triggering innate immu-
nity are called pattern recognition receptors (PRRs), since they recognise specific structures 
unique to microbes that are not found in the host. These invariant structures are termed microbe 
associated molecular patterns (MAMPs). To date, a broad variety of different PRRs have been 
identified in mammals. These PRRs can either be membrane-bound, like the Toll-like receptors 
(TLRs) or C-type lectin receptors (CLRs) but also cytosolic, like the nucleotide-binding domain, 
leucine-rich repeat containing receptors (NLRs) or RIG-I-like receptors (RLRs). To date, several 
mutations in PRRs and downstream signalling components associated with severe immune-
related diseases were described, in particular in TLR and NLR signalling, uncovering their impor-
tance in innate immune recognition and subsequent clearing of infecting pathogens (reviewed in 
Netea et al., 2012; Kufer and Sansonetti, 2011). 
 
1.2 Membrane‐bound Pattern Recognition Receptors 
Among the membrane-bound PRRs, TLRs are probably the best studied family. The first human 
TLR, TLR 4, was identified in 1997 (Medzhitov et al., 1997). TLRs are closely related to the inter-
leukin (IL)-1 receptor and the Drosophila Toll receptor which was previously reported to mediate 
anti-fungal immunity in flies (Medzhitov et al., 1997; Lemaitre et al., 1996). The TLR family in 
humans comprises 10 different family members, whereas 12 different TLRs have been reported 
in mice. All TLRs are type I transmembrane proteins and consist of an extracellular leucine-rich-
repeat (LRR) domain, a central transmembrane domain and a cytoplasmic Toll/interleukin-1 re-
ceptor (TIR) domain (Kumar et al., 2011a). Although TLRs mediate extracellular pathogen recog-
nition, they are not exclusively located in the plasma membrane. In fact, among the 10 different 
TLRs in humans, TLR1, TLR2, TLR4, TLR5 and TLR6 are expressed at the cell surface, whereas 
TLR3, TLR7, TLR8 and TLR9 are expressed in the endocytic compartment (Kumar et al., 2011a). 
TLRs are able to recognize a broad variety of microbe-associated molecular patterns (MAMPs), 
including lipopeptides, detected by TLR2 together with TLR1 or TLR6 (Takeda et al., 2002), nu-
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cleic acids, detected by TLR3 (Alexopoulou et al., 2001), TLR7, TLR8 (Heil et al., 2004) or TLR9 
(Hemmi et al., 2000), as well additional bacterial derived products, including LPS, detected by 
TLR4 (Medzhitov et al., 1997) or flagellin, detected by TLR5 (Mizel et al., 2003; Smith et al., 2003; 
Hayashi et al., 2001).  
Upon activation by their ligands, dimerisation was reported for at least some TLR recep-
tors, including TLR2 with TLR1 and TLR6 (Jin et al., 2007; Takeda et al., 2002), TLR3 (Wang et 
al., 2012) and TLR4 (Park et al., 2009) to mediate downstream signalling by recruitment of TIR-
domain containing adaptor molecules, such as myeloid differentiation primary response gene 88 
(MyD88), Toll/IL-1R domain containing adaptor inducing IFN- (TRIF), TIR domain contain-
ing adaptor protein (TIRAP) and TRIF-related adaptor molecule (TRAM) (Kumar et al., 2011a; 
Saitoh et al., 2004b; Saitoh et al., 2004a). Except TLR3, all TLRs are able to recruit MyD88, which 
activates nuclear factor “kappa-light-chain-enhancer” of activated B-cells (NF-B) or mitogen-
activated protein kinase (MAPK) pathways. TRIF, in contrast, is recruited to TLR3 and TLR4 
following activation and triggers downstream NF-B and interferon regulatory factor 3 (IRF3) 
signalling, resulting in type I interferon and cytokine production (Kawai and Akira, 2010). TRAM 
and TIRAP serve as adaptor molecules, important for the specific recruitment of MyD88 and 
TRIF, and provide a basis for diversity in TLR signalling (Kumar et al., 2011a). Among all TLRs, 
TLR4 is the only TLR which is able to bind all of the four adaptor proteins and requires addi-
tional molecules for LPS-recognition, including LPS-binding protein (LBP), CD14 and myeloid 
differentiation protein 2 (MD-2) (Peri and Piazza, 2012; Akashi-Takamura and Miyake, 2008; 
Shimazu et al., 1999). TLR signalling in general can be divided into a MyD88-dependent and a 
MyD88-independent (TRIF-dependent) signalling cascade.  
In the MyD88-dependent pathway, MyD88 activates the insulin receptor associated 
kinase 4 (IRAK4). Subsequently, IRAK 1 and 2 are phosphorylated and recruited to form an ac-
tive signalling complex together with TNF-receptor associated factor 6 (TRAF6). TRAF6 is an 
E3-Ligase which assembles lysine 63-linked polyubiquitin chains on itself together with IRAK1. 
For that purpose, two additional enzymes, the ubiquitin-activating enzyme Ubc13 and the ubiq-
uitin-conjugating enzyme Uev1A are recruited and form the fully active ubiquitin-transfer com-
plex together with TRAF6 (refer to figure 1.1; MyD88-dependent TLR signalling). Subsequently, 
ubiquitinated TRAF6 acts as a signalling mediator in TLR signalling and interacts with TAK1, a 
member of the mitogen-activated protein kinase kinase kinase (MAPKKK) family (Yamaguchi et 
al., 1995). Two proteins called TAB1 and TAB2 have been identified to play crucial roles as scaf-
folding proteins for TAK1 and bind to ubiquitinated TRAF6 (Akira and Takeda, 2004). The acti-
vated TAK1/TRAF6 complex subsequently mediates phosphorylation of downstream targets 
such as the IB kinase complex (IKK) and MAPKs (Ninomiya-Tsuji et al., 1999). The IB kinase 
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complex (IKK) consists of IKK-, IKK- and NF-B essential modulator (NEMO or IKK-γ) 
and is responsible for phosphorylation of the inhibitor of NF-B (IB). Phosphorylation of IB 
leads to its degradation and to the release of bound p65/p50, which initiates transcription of 
early-phase NF-B responsive genes (Karin and Ben-Neriah, 2000). A schematic overview of the 
processes starting from TLR dimerization upon ligand binding and ending up in NF-B activa-
tion is depicted in figure 1.1. 
The MyD88-independent or TRIF-dependent pathway mainly plays a role in nucleic acid 
recognizing TLRs, such as TLR3, as well as partly in TLR4 signalling, resulting in IRF3-
dependent type I interferon activation and late phase NF-B activation (Akira and Takeda, 2004). 
It has been shown that noncanonical IKKs, for example the kinase IKK-ε, as well as the TANK-
binding kinase-1 (TBK1) mediate activation of IRF3 downstream of TRIF (Fitzgerald et al., 
2003b; Fitzgerald et al., 2003a; Sharma et al., 2003a; Yamamoto et al., 2002). Phosphorylation in its 
C-terminal regulatory domain leads to dimerisation and nuclear translocation of IRF3 where it 
acts as a transcription factor in conjunction with co-activators such as p300 and CREB-binding 
protein for early phase IFN- release. Furthermore, IRF3 also induces and cooperates with an-
other IRF called IRF7, which is involved in later phase IFN- and IFN- expression (Akira and 
Takeda, 2004; Sato et al., 2000). Taken together, TRIF is involved in type I IFN production, but 
can also trigger late phase NF-B activation via at least two different MyD88-independent path-
ways (Akira and Takeda, 2004).  
The physiological importance of TLR signalling is highlighted by hereditary cases of se-
vere diseases caused by pathogen infection (reviewed in Casanova et al., 2012). Well studied ex-
amples are mutations in MyD88 and IRAK4, abolishing functional protein production. The ab-
sence of these proteins result in impaired cytokine production, followed by increased bacterial 
infection diseases (reviewed in Netea et al., 2012). Interestingly, MyD88-IRAK4 deficiency is 
most problematic in early childhood, but less in the adulthood, indicating the development of 
adaptive immune responses over time (Netea et al., 2012; Bousfiha et al., 2010). Another example 
affects the MyD88-independent/TRIF-dependent signalling pathway downstream of TLR3, in-
cluding mutations in TLR3 itself, in TRIF and in additional downstream molecules. These pa-
tients are highly susceptible to herpesvirus encephalitis, but not to diseases caused by other in-
fecting pathogens, most likely due to altered type I IFN release (Netea et al., 2012; Bousfiha et al., 
2010; Zhang et al., 2007). 
A second group of transmembrane receptors are Dectin-1 and Dectin-2, two members of 
the C-type lectin superfamily. Although, this superfamily consists of 17 subgroups with more 
than 1000 proteins, in mammals only Dectin-1 and Dectin-2 seem to function as PRRs to detect 
microbial derived molecules. C-type lectin receptors (CLRs) consist of an extracellular stalk re-
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gion, a central transmembrane domain and a cytoplasmic signalling region (reviewed in Sancho 
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Although this cytoplasmic region can harbour different signalling motifs with mostly unknown 
signalling functions, the role of Dectin-1 and Dectin-2 with an immunoreceptor tyrosine-based 
activation motif (ITAM) and a hemITAM motif, respectively, has been linked to innate immunity 
(Sancho and Reis e Sousa, 2012). Both Dectin-1 and Dectin-2 are activated by the fungal cell wall 
components -1-3-glycans and -mannose, respectively. Upon activation, they dimerize and re-
cruit the tyrosine kinase Syk, which is able to activate a variety of signalling pathways, like NF-B 
via the adaptor CARD9, MAPK pathways, the transcription factor nuclear factor of activated T 
cells (NFAT) or reactive oxygen species (ROS) production (Sancho and Reis e Sousa, 2012). Im-
portantly, Dectin-1 and Dectin-2 do not only function as PRRs to trigger innate immunity, but 
can also impact cell migration, phagocytosis or cargo transport in general (Sancho and Reis e 
Sousa, 2012). 




Even though membrane bound PRRs are able to cope with a variety of different pathogens, 
when pathogens enter the cytoplasm, these receptors become useless.  
From that point on, intracellular PRRs undertake pathogen recognition and innate immunity ac-
tivation. Examples are the RIG-I-like receptors (RLRs), DNA-binding proteins like the DNA-
dependent activator of IFN-regulatory factors (DAI), members of the PYHIN protein family, 
such as absent in melanoma 2 (AIM2) and nucleotide-binding domain-leucine-rich repeat-
containing proteins (NLRs) (Schattgen and Fitzgerald, 2011; Wilkins and Gale, 2010). 
Most of these cytoplasmic receptors are activated by pathogen-derived molecules. RLRs and 
DNA receptors are responsible for viral nucleic acid recognition whereas NLR proteins are 
mainly, but not exclusively, activated upon stimulation by bacterial-derived products and danger 
molecules. In the following paragraph, the different protein families and their signalling pathways 
will be briefly introduced. 
The RLR family consists of three different members, namely retinoic-acid inducible gene 
I (RIG-I), melanoma differentiation associated gene 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP2). RLRs are expressed ubiquitously in most cell types and are closely related 
to each other. Moreover, they share a similar structure belonging to the DExD/H box-containing 
RNA helicase family. They consist of a C-terminal regulatory domain (RD), which is important to 
confer recognition specificity for 5'-ppp dsRNA bound by the central helicase domain. Further-
more, RIG-I and MDA5 have two additional N-terminal caspase recruitment and activation 
(CARD) domains (Schmidt et al., 2011). Although LGP2 lacks the N-terminal CARD domain and 
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was thus proposed to have inhibitory function (Komuro and Horvath, 2006; Rothenfusser et al., 
2005), another study reported a defect in type I IFN response in LGP2-/- mice upon viral infec-
tion (Venkataraman et al., 2007).  
To date, the molecular basis of ligand binding to RIG-I has been investigated in great de-
tail. In vitro assays revealed, that RIG-I interacts with 5’-ppp-ssRNA and dsRNA in an ATP-
independent manner through its C-terminal repressor domain (RD) and helicase domain (Gee et 
al., 2008; Hornung et al., 2006; Pichlmair et al., 2006). Subsequent ATP binding induces confor-
mational changes, leading to exposure of the CARD domains (Kowalinski et al., 2011; Luo et al., 
2011; O'Neill and Bowie, 2011). Due to structural similarities, a related mechanism is also plausi-
ble for other RLRs (O'Neill and Bowie, 2011). In contrast to RIG-I, MDA5 is selectively acti-
vated by the dsRNA mimic poly(I:C) (Yoneyama and Fujita, 2009; Kato et al., 2006). Although 
detailed information of the subsequent ATP-dependent activation is still missing, it has been es-
tablished, that both RIG-I and MDA5 interact through homotypic CARD-CARD interactions 
with the signalling-adaptor molecule IPS-1 (also known as MAVS, VISA or Cardif) (Kawai et al., 
2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005). IPS-1 itself is associated to the outer 
mitochondrial membrane and consists of an N-terminal CARD domain, a central proline-rich-
region (PRR) as well as a C-terminal transmembrane domain which is important for its function 
(Seth et al., 2005). RIG-I and MDA5 activation result in type I IFN production, mediated by the 
adaptor protein TRAF3 (refer to figure 1.3; right part). An interaction between IPS-1 and TRAF3 
was reported to be essential for type I IFN via recruitment of the kinases (TANK)-binding kinase 
1 (TBK1) and IKK- with subsequent activation of the transcription factors IRF3/7 (Fitzgerald et 
al., 2003b; Sharma et al., 2003b). Moreover, RIG-I and MDA5 also activate NF-B, likely by re-
cruitment of TRAF2 and TRAF6 (Xu et al., 2005). This signalling platform consists of several 
additional factors including Fas-associated death domain (FADD), receptor interacting protein 1 
(RIP1), as well as of proteins involved in the TNF-receptor (TNFR)-mediated signalling com-
plex, for example TNFR-associated DD (TRADD) (Yoneyama and Fujita, 2009). For complete 
RIG-I activation, another adaptor protein called stimulator of interferon genes (STING), also 
known as mediator of IRF-3 activation (MITA), interacts directly with RIG-I, thus functioning as 
a scaffold (Ishikawa and Barber, 2008; Zhong et al., 2008) (also refer to Figure 1.3; right part).  
 Another group of intracellular nucleic acid receptors mediates DNA recognition. The fact 
that dsDNA occurs in the cytoplasm only during a pathogen infection makes it an efficient target 
for innate immune responses. Moreover, cytoplasmic DNA is able to trigger different pathways 
(reviewed in Hornung and Latz, 2010). First, DNA receptors can induce transcriptional repro-
gramming, i.e. NF-B activation or IRF activation, second, dsDNA can be transcribed by RNA 
polymerase III to elicit RIG-I (Ablasser et al., 2009; Chiu et al., 2009) and finally, dsDNA can 
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induce IL-1 processing by activation of the AIM2 inflammasome (Burckstummer et al., 2009; 
Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Roberts et al., 2009). 
The first cytoplasmic receptor recognized to function as a dsDNA receptor was DNA-
dependent activator of IRFs (DAI; also known as ZBP1) (Takaoka et al., 2007). DAI is able to 
induce type I IFN responses in an IRF3-dependent manner (Takaoka et al., 2007). However, DAI 
knock-down cells responded normally to DNA virus infection, thus it is likely that more than one 
receptor has evolved to detect dsDNA (Hornung and Latz, 2010; Wang et al., 2008). 
In 2009, Chiu and colleagues, as well as Ablasser and colleagues, unveiled a dsDNA-
dependent type I IFN response, which was RIG-I-, MAVS- and IRF3-dependent. During the 
study, they uncovered a mechanism, by which AT-rich cytoplasmic DNA serves as a template for 
de novo synthesis of RNA by DNA-dependent RNA polymerase III. The de novo synthesized RNA 
then activates RIG-I and induced type I IFN responses (Ablasser et al., 2009; Chiu et al., 2009). 
Both studies not only elucidated a new pathway of dsDNA recognition, but also solved a long-
standing mystery why DNA-dependent RNA polymerase is present in the cytoplasm, where 
normally no DNA is present (Ablasser et al., 2009; Chiu et al., 2009). 
 Finally, dsDNA recognition is also mediated by the recently discovered PYHIN protein 
family with its most prominent members absent in melanoma 2 (AIM2) and interferon inducible 
protein (IFI16). This protein homooligomerizes upon activation and interacts with the apoptosis-
associated speck like protein containing a CARD (ASC) to form multi-protein structures called 
inflammasomes (refer to figure 1.3). 
PYHIN proteins consist of an N-terminal PYRIN domain and one or more C-terminal HIN200 
domains. The C-terminal HIN200 domain is able to bind directly to dsDNA, thus, this family 
appears to be composed of intracellular nucleotide sensors. In human, the PYHIN family con-
sists of 4 members and the first PYHIN protein discovered to form inflammasome structures 
was AIM2 (Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Rob-
erts et al., 2009). Another PYHIN protein, IFI16, was discussed to be involved in type I IFN re-
sponses against dsDNA (Unterholzner et al., 2010) and later inflammasome formation by IFI16 
was observed. Interestingly, the IFI16 inflammasome is the only nuclear inflammasome reported 
so far (Kerur et al., 2011).  
 
1.4 Nucleotide‐binding domain, leucine‐rich repeat containing proteins (NLRs) 
NLR proteins are the largest family of cytosolic PRRs in mammals, including 22 members in hu-
mans (Ting et al., 2006). They have a common tripartite structure, which consists of an N-
terminal effector domain, a central ATPase domain present in NAIP, CIITA, the fungal protein 
HET-E and the telomerase subunits TP-1 (NACHT domain) and a C-terminal leucine-rich re-
INTRODUCTION 
8 
peat containing region (reviewed in Kufer and Sansonetti, 2011; Koonin and Aravind, 2000). 
NLR proteins belong to the STAND subclass of AAA ATPases, thus they are able to bind and 
hydrolyse ATP (reviewed in Kufer and Sansonetti, 2011; Danot et al., 2009; Hanson and White-
heart, 2005). The detailed function of ATP-binding and hydrolysis in NLR activation is not well 
understood, but structural data on the closely related human apoptotic protease-activating factor-
1 (Apaf-1) suggests a model in which the N-terminal effector domain is buried by the C-terminal 
WD40 region in an ADP-dependent manner and thus is not accessible for downstream signalling 
in the inactive molecule (Riedl and Salvesen, 2007; Bao et al., 2005). Upon binding of the Apaf-1 
ligand cytochrome c and upon exchange of ADP for ATP, Apaf-1 forms an oligomeric complex 
termed apoptosome. This apoptosome mediates caspase-9 activation and triggers apoptotic cell 
death (Riedl et al., 2005). Inactivation of Apaf-1 then is brought about by ATP hydrolysis result-
ing in the complex disassembly. 
On the basis of their N-terminal effector domains, NLR proteins can be divided into three dif-
ferent groups. The two main groups, the Nodosome or NLRC NLRs and the Inflammasome or 
NLRP NLRs harbour an N-terminal CARD or PYRIN domain, respectively (reviewed in Kufer, 
2008; Fritz et al., 2006). The third group is characterized by an effector domain excluding CARD 
or PYRIN. The neuronal apoptosis-inhibitory protein (NAIP) for example harbours a baculovi-
rus inhibitor of apoptosis domain (BIR) (Mercer et al., 2000), whereas NLRX1 possesses a mito-
chondrial targeting sequence (Tattoli et al., 2008).  
However, some NLRs also harbour a less characterized N-terminal domain, as for example 
NLRC3 or NLRC5. A schematic overview of NLR proteins is depicted in figure 1.2.  
Interestingly, NLR proteins are highly conserved and similar proteins can also be found in 
plants. Notably, plants lack an adaptive immune system, thus immune responses completely rely 
on innate immune detection mediated by membrane-bound PRRs and NLR proteins, called resis-
tance proteins (R-proteins) as key players. These R-proteins have a similar structure, consisting of 
an N-terminal effector domain, which can either be a coiled-coil (CC) or Toll/interleukin-1 (TIR) 
domain, a central nucleotide binding domain (NB-ARC) and C-terminal leucine rich repeats 
(LRRs). Analogous to animal NLR proteins, they serve as immune receptors, although plant 
NLRs rather sense modified host proteins (‘modified self’ model) and pathogen-derived effector 
proteins to provoke effector triggered immunity (ETI) (reviewed in Maekawa et al., 2012). 
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The Nodosome NLR family is characterized by the presence of an N-terminal caspase activation 
and recruitment domain (CARD). This domain was first identified in an alignment study from 
1996 by Bucher and colleagues and was found in proteins involved in apoptotic signalling 




The so far most extensively studied members of the Nodosome NLR family are NOD1 
and NOD2. Both protein possess the typical tripartite NLR structure, except that NOD2 har-
bours a prolonged N-terminus consisting of two CARD domains, in contrast NOD1 possesses 
only one CARD domain (Ogura et al., 2001; Inohara et al., 1999). The first functional characteri-
zations of NOD1 and NOD2 were published by the Nuñez group in 1999 and 2001, respec-
tively, showing that both proteins activate NF-B by involvement of the receptor interacting 
protein kinase 2 (RIP2) (Ogura et al., 2001; Inohara et al., 2000; Inohara et al., 1999). The elicitors 
for NOD1 and NOD2 were identified in 2003, when several groups reported distinct substruc-
tures of peptidoglycan (PGN) that are recognized by NOD1 and NOD2 (Chamaillard et al., 2003; 
Girardin et al., 2003b; Girardin et al., 2003a; Inohara et al., 2003). The minimal structure that is 
recognized by NOD1 was identified as γ-D-glutamyl-meso-diaminopimelic acid (ie-DAP), a 
structure which is found in PGN of Gram-negative bacteria (Chamaillard et al., 2003; Girardin et 
al., 2003b). The minimal structure that elicits NOD2 is muramyl dipeptide, present in PGN of 
both Gram-positive and Gram-negative bacteria (Girardin et al., 2003a; Inohara et al., 2003). The 
LRR region is pivotal for the recognition of PGN in both NOD1 and NOD2 (Girardin et al., 
2005; Tanabe et al., 2004) and there is now evidence for a direct interaction between NOD1 and 
TriDAP (Laroui et al., 2011) and NOD2 and MDP (Grimes et al., 2012; Mo et al., 2012). Upon 
recognition of PGN fragments, NOD1 and NOD2 are thought to undergo conformational 
changes resulting in an interaction with the receptor interacting protein kinase 2 (RIP2) (Ogura et 
al., 2001; Inohara et al., 2000). Subsequently, RIP2 gets ubiquitinated at lysine 63, which serves as 
a docking site for the TAK1/TAB2/TAB3 complex. Although the E3 ligase being responsible 
for this event remains somewhat unclear, it was initially proposed that TRAF2, TRAF5, TRAF6 
and ITCH are responsible for this event (Tao et al., 2009; Hasegawa et al., 2008; Abbott et al., 
2007). Recently it became evident that cellular inhibitor of apoptosis 1 (cIAP1) and cellular in-
hibitor of apoptosis 2 (cIAP2) as well as the X-linked inhibitor of apoptosis (XIAP) play an es-
sential role in RIP2 ubiquitination (Bertrand et al., 2009; Krieg et al., 2009) and a role for the linear 
ubiquitin assembly complex (LUBAC) in NOD2 signalling was reported (Damgaard et al., 2012). 
Similar to TLR signalling, the TAB-TAK complex activates the IKK complex, consisting of 
IKK-, IKK- and IKK- (NEMO). Subsequently, IKK- and IKK- phosphorylate IB, 
leading to ubiquitination and degradation. As a result, the canonical NF-B subunits p50 and p65 
can translocate to the nucleus and bind to NF-B-specific promoter sites (reviewed in Correa et 
al., 2012). 
NOD1 and NOD2 are not only directly controlled through binding of the elicitor, but 
further by factor acting downstream in the signalling cascades. Some examples are the de-
ubiquitinating enzyme A20, which de-ubiquitinates RIP2 and inhibits NF-B activation (Hase-
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gawa et al., 2008). AAMP that inhibit both NOD1- and NOD2-mediated NF-B activation 
(Bielig et al., 2009) and Erbin that exerts an inhibitory function specific for NOD2-mediated NF-
B signalling (Kufer et al., 2006; McDonald et al., 2005). To conclude, even though NOD1 and 
NOD2 were identified over 10 years ago, the details of their signalling pathways still remain un-
clear. 
Interestingly, several mutations in the NOD1-encoding gene CARD4 and the NOD2-
encoding gene CARD15 are linked to severe inflammatory disorders. Polymorphisms in CARD4, 
for example, are linked to asthma and increased levels of serum IgE and mutations in CARD15 
are associated with increased susceptibility to Crohn’s Disease (CD), Blau syndrome (BS) and 
early-onset sarcoidosis (EOS). The increased susceptibility to CD is caused by several amino acid 
substitutions in or near the LRR of NOD2, results in a loss-of-function mutation, whereas BS 
and EOS are linked to constitutive NF-B activation, triggered by gain-of-function NOD2 vari-
ants (reviewed in Franchi et al., 2009). 
 
1.4.2 The Inflammasome NLRs 
The group of inflammasome NLRs, or NLRPs, is the largest sub-group of NLR proteins with 
similar PYRIN-domain containing structures. They functionally differ from the Nodosome 
NLRs since they are responsible for IL-1 and IL-18 processing, two cytokines that play crucial 
roles in immunity. Inflammasomes are high-molecular-weight structures, which assemble in the 
cytoplasm. They consist of NLRP proteins together with an adaptor protein called apoptosis-
associated speck-like protein (ASC) and recruit pro-caspase-1. This in turn leads to activation of 
caspase-1 and subsequent cleavage of pro-IL-1 or pro-IL-18 into the biological active forms IL-
1 and IL-18 (reviewed in Gross et al., 2011). Although most NLRP proteins are still uncharacter-
ized, inflammasome formation was reported for NLRP1, NLRP3, NLRP6 and NLRP12. Addi-
tionally, inflammasome assembly was also observed for NLRC4, a CARD-containing NLR pro-
tein, as well as for a recently discovered protein family, called PYHIN proteins (Rathinam et al., 
2012; Schattgen and Fitzgerald, 2011). As depicted in figure 1.3, inflammasome NLR proteins 
form different inflammasome complexes. 
The best studied inflammasome is the NLRP3 inflammasome (Martinon et al., 2002). 
Upon activation and oligomerization, NLRP3 recruits the adaptor protein ASC (Mariathasan et 
al., 2004). ASC binds to NLRP3 through its PYRIN domain, providing an exposed CARD do-
main that is important for caspase-1 recruitment. Caspase-1 is expressed as a zymogen and oli-
gomerization with the inflammasome activates a process known as autoproteolysis, leading to 
self-cleavage and caspase-1 activation (Cohen, 1997). 
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NLRP3 inflammasome signalling is tightly controlled on different levels of activation. For 
example, it has been shown that expression of pro-IL-1is highly inducible by LPS (Bauernfeind 
et al., 2009; Unlu et al., 2007). Moreover, expression of NLRP3 itself is inducible by LPS in an 
NF-B-dependent manner, a process that is necessary but not sufficient for NLRP3 inflam-
masome activation (Bauernfeind et al., 2009). Finally, inflammasome formation also depends on 
an activating stimulus. For the best-studied member NLRP3 several stimuli have been reported 
to trigger inflammasome assembly. On the one hand, NLRP3 is activated by several pathogens 
(i.e. Staphylococcus aureus, Listeria monocytogenes, Klebsiella pneumoniae, Candida albicans and influenza A 
virus) (Rathinam et al., 2012). On the other hand, host-derived cellular molecules referred to as 
danger molecules activate the inflammasome. An important role in this process plays extracellular 
ATP, hyaluronan, amyloid- fibrils as well as uric acid crystals (Gasse et al., 2009; Yamasaki et al., 
2009; Halle et al., 2008; Mariathasan et al., 2006). 
Due to this broad diversity of elicitors a direct binding of the elicitors to the inflam-
masome seems unlikely. Rather, three models were proposed, in which the stimuli mentioned 
above trigger either potassium (K+) efflux, ROS production or phagolysosomal destabilization, all 
of them resulting in NLRP3 inflammasome formation (reviewed in Rathinam et al., 2012; Jin and 
Flavell, 2010). 
Interestingly, the CARD-containing NLRC4 protein is also able to form inflammasomes, 
but in contrast to NLRP3, the NLRC4 inflammasome is independent of ASC, since caspase-1 is 
able to directly bind to the N-terminal CARD domain of NLRC4. It was reported, that the 
NLRC4 inflammasome assembles upon bacterial stimuli. Several groups analysed assembly upon 
stimulation with flagellin derived from many different bacteria but NLRC4 inflammasomes also 
assemble after detection of a critical type III secretion system (T3SS) protein, which is shared by 
many different bacteria (Gong and Shao, 2012; Miao et al., 2010). The detailed mechanism of 
NLRC4 activation was long time veiled with no evidence for direct binding of flagellin to 
NLRC4. In 2011, two groups reported a necessity of NAIP2 and NAIP5 in recognition of bacte-
rial T3SS protein and flagellin, respectively. Furthermore, direct binding between NLRC4 and 
NAIP2 or NAIP5 was observed, which in turn bind bacterial derived products, demonstrating 
that a receptor-ligand-model mediated by additional proteins could be conceivable for activation 
of other inflammasomes as well (Kofoed and Vance, 2011; Zhao et al., 2011) (refer to figure 1.3). 
NLRP6 and NLRP12 were one of the first proteins to be referred to function as inflam-
masomes after transfection and overexpression (Grenier et al., 2002; Wang et al., 2002). To date, 
there has been no activator for NLRP6 identified yet, but recent work demonstrated the in-
volvement of NLRP6 in intestinal homeostasis including its function as a negative regulator of 
inflammatory signalling (Anand et al., 2012; Chen et al., 2011; Elinav et al., 2011; Normand et al., 
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2011). NLRP12 was reported to function as an antagonist of proinflammatory signals, induced by 
TLR, but its involvement in migration of dendritic cells and myeloid cells was also reported. 
Nevertheless, it seems to be dispensable for caspase-1 activation upon different stimuli (reviewed 
in Rathinam et al., 2012). 
NLRP1 is unique among NLR proteins, since the NLRP1 inflammasome can bypass the 
necessity of the adaptor protein ASC because of a C-terminal CARD domain in the NLRP1 pro-
tein. Nevertheless, ASC is able to enhance NLRP1 inflammasome activity (Rathinam et al., 2012). 
Interestingly, NLRP1 harbours an additional domain between LRR and CARD, called function-
to-find (FIIND) (refer to figure 1.2). Even though its function remains to be elucidated, autopro-
teolytical cleavage can be observed, resulting in a CARD-lacking NLRP3-like NLRP1 protein 
(D'Osualdo et al., 2011). The only known activator of human NLRP1 so far is the bacterial pepti-
doglycan component muramyl dipeptide (MDP), inducing inflammasome formation in a NOD2-
dependent manner in the presence of ATP (Faustin et al., 2007; Hsu et al., 2008). Confusingly, 
murine NLRP1 lacks the N-terminal PYRIN domain (D'Osualdo and Reed, 2012). 
Finally, PYHIN family members also assemble to inflammasomes by recruitment of the 
adaptor proteins ASC, similar to NLRP3 (refer to section 1.3) (reviewed in Schattgen and Fitz-
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As previously introduced, most NLR proteins are involved in either NF-B signalling or IL-
1/IL-18 processing. Nonetheless, other functions beyond pathogen recognition have been re-
ported for several NLRs (reviewed in Kufer and Sansonetti, 2011). The best characterized NLR 
protein with a PRR-unrelated function is the MHC class II transcriptional activator (CIITA). It 
shares the typical NLR tripartite structure, including NACHT domain and LRR domain, but har-
bours an N-terminal transcription activation domain (AD) followed by a 
proline/serine/threonine-rich region (P/S/T) (reviewed in Krawczyk and Reith, 2006). 
CIITA was originally discovered by an expression cloning approach using MHC class II 
deficient R2.25 cells, derived from the Burkitt Lymphoma B cell line Raji (Steimle et al., 1993; 
Hume and Lee, 1989; Long et al., 1984; Accolla, 1983). Steimle and colleagues identified a cDNA 
that completely restored MHC class II expression, termed MHC class II transcriptional activator 
(CIITA) (Steimle et al., 1993). Polymorphisms in CIITA are associated with a severe immunodefi-
ciency in patients, characterized by the lack of MHC class II expression, hence called bare lym-
phocyte syndrome (BLS) (Steimle et al., 1993). Interestingly, the genes encoding the MHC class II 
molecules are intact in these patients, thus mutations were supposed to involve genes having a 
regulatory function for MHC molecule transcription (Krawczyk and Reith, 2006; Reith and 
Mach, 2001). 
MHC molecules are pivotal for antigen presentation in antigen-presenting cells (APCs), 
like macrophages and dendritic cells (DCs) (Vyas et al., 2008). They are responsible for the trans-
port and cell-surface-presentation of small peptides to T cell receptors (TCRs) (reviewed in van 
der Merwe and Dushek, 2010). Depending on the source, antigen presentation is performed by 
two different pathways. Cytosolic antigens deriving from intracellular bacteria or viruses as well 
as cellular proteins are presented at the cell surface via the MHC class I pathway, whereas exoge-
nous antigens present in the endocytic compartment are presented on the cell surface via the 
MHC class II pathways. Although the principle of antigen presentation is similar in class I and 
class II, the pathways differ from each other in some major aspects. A brief overview is depicted 
in figure 1.4. 
Antigens presented by MHC class II molecules are mainly of exogenous origin. They are 
taken up by phagocytosis and undergo endosomal degradation. MHC class II molecules are as-
sembled in the ER and are composed of an chain and a -chain, which are further stabilized 
by an invariant chain (li). Subsequently, the complex of MHC class II molecule and li is trans-
ported to a late endosomal compartment, termed MHC class II compartment (MIIC) (refer to 
figure 1.4; right part). This compartment is further provided with extracellular antigens by en-
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dosomal fusion. Here, li is digested and only a small peptide termed class II-associated li peptide 
(CLIP) remains in the antigen-binding groove. Afterwards a helper molecule, HLA-DM, mediates 
the exchange of CLIP with an antigen, and as a consequence, the loaded MHC class II molecules 
are transported to the cell surface, where foreign antigens activate CD4+ T cells (reviewed in 
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MHC  class  II molecules  are  transported  to  a  special  compartment,  termed MHC  II  compartment 
(MIIC), where  loading of MHC class  II molecules with the peptides takes place. Loaded MHC class  II 





MHC class I molecules are key players in adaptive immune responses toward cytoplasmic 
pathogens, like certain bacteria and viruses. Antigens presented by MHC class I molecules are 
typically cytosolic and are generated by proteasomal degradation of proteins. Nontheless, DCs 
are uniquely able to take up exogenous peptides and present these via the MHC class I pathway, a 
process that is called cross-presentation. How this is mediated in detail remains to be elucidated, 
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currently both passive and active transport of peptides from phagosomes into the cytoplasm are 
discussed (Vyas et al., 2008). Of note, many virus-infected cells, but notably also transformed cells 
show reduced or impaired MHC class I molecule expression, resulting in escaping of immuno-
surveillance, although the underlying mechanism is still poorly understood (Reinis, 2011). How-
ever, complete absence of MHC class I antigen presentation typically results in natural killer (NK) 
cell-mediated lysis, known as “missing-self” hypothesis (Kumar and McNerney, 2005). 
For that reason, antigen presentation of host-derived peptides by MHC class I molecules is of 
great importance to protect the cell from natural killer (NK) cell-mediated lysis. This protection is 
mediated by immediate degradation of newly synthesized proteins with subsequent loading of the 
peptides onto MHC class I moelcules (Reits et al., 2000; Schubert et al., 2000). Degradation is 
mediated by the 26S proteasome, which can either be supported by additional proteasomes called 
immunoproteasomes, or different subunits of the 20S proteasome subunit can be displaced by 
other immune specific subunits (Sijts and Kloetzel, 2011). Subsequently, the peptide fragments 
are transported into the endoplasmic reticulum (ER) by the peptide transporter TAP, where the 
MHC class I molecules are present as membrane-bound proteins stabilized by a subset of chap-
erones (figure 1.4; left part). In brief, the classical MHC class I molecules consist of heavy chains 
(encoded by the genes HLA-A, HLA-B and HLA-C) and one 2-microglobulin chain. Peptide 
fragments are further cleaved to the appropriate loading size by aminopeptidases. The loading of 
peptides is mediated by the peptide-loading complex (PLC), including TAP, Tapasin (a chaper-
one) and the MHC class I molecule. Subsequently, the antigen-loaded molecules are transported 
to the cell surface via the Golgi-network, where antigen-bound MHC I molecules are detected by 
specific T-cell receptors on CD8+ T cells (reviewed in Neefjes et al., 2011). A brief summary is 
depicted in figure 1.4. 
In order to preserve an uncontrolled immune reaction caused by APCs, such a powerful 
system has to be tightly regulated. This regulation is maintained on the one hand by the furnish-
ing of antigens (for example proteasome modifications), but on the other hand, the MHC mole-
cule expression itself is tightly regulated. In general, expression of MHC molecules is induced by 
IFN-, but the principle is slightly different between MHC class I and MHC class II. MHC class I 
gene promoters posses an interferon stimulatory response element (ISRE), which is occupied by 
IRF1 and triggers MHC class I expression upon IFN- stimulation (refer to figure 1.6) (Gobin et 
al., 1999). Although the ISRE element is lacking in MHC class II gene promoters, these genes are 
also highly inducible upon IFN- stimulation, similar to MHC class I molecules. Responsible for 
the IFN-–dependent induction of MHC class II genes is CIITA, which itself is highly inducible 
by IFN- (Muhlethaler-Mottet et al., 1997; Steimle et al., 1994). Beside the involvement of CIITA 
in MHC class II gene expression, another protein was discovered in 1995, termed regulatory fac-
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tor x 5 (RFX-5) (Steimle and Mach, 1995). In the following years, two additional proteins of the 
regulatory factor x family were described being indispensable for MHC expression, termed RFX-
AP and RFX-ANK (or RFX-B) (Nagarajan et al., 1999; Masternak et al., 1998; Durand et al., 
1997). These proteins, termed RFX proteins, assemble to a trimeric RFX complex, called en-
hanceosome, which interacts with the MHC class II promoter. The MHC class II promoter con-
sists of an S, X1, X2, Y motif (refer to figure 1.5) and the enhanceosome complex was reported 
to bind specifically to the X2-box inside of this motif (Steimle et al., 1995). Together with addi-
tional DNA-binding factors called X2-binding protein (X2BP; a complex of cyclic-AMP-
responsive-element-binding protein (CREB) and activating transcription factor (ATF)) (Moreno 
et al., 1999; Moreno et al., 1995) and nuclear factor binding to the Y box (NF-Y), as well as with 
an intact S-box sequence (Muhlethaler-Mottet et al., 2004), they assemble a platform to recruit 
CIITA. CIITA as a non-DNA-binding co-activator is now able to recruit the general transcrip-
tion machinery and elongation factors, as well as histone-modifying enzymes to activate MHC 
class II transcription (reviewed in Wright and Ting, 2006; Reith et al., 2005). A schematic over-
view is depicted in figure 1.5. 
For the function of CIITA, nuclear localization that relies on a functional NACHT do-
main is a prerequisite. In contrast to other NLR proteins, CIITA has a significant homology to 
GTP-binding proteins of the Ras-superfamily and CIITA was shown to bind GTP, rather than 
ATP (Chin et al., 1997). Mutants lacking GTP-binding and hydrolysis activity loose their ability to 
shuttle to the nucleus (Harton et al., 1999). Moreover, the LRR region and the N-terminal domain 
contribute to nuclear localization. An in-depth-analysis of the LRR region was performed by the 
group of Viktor Steimle, which identified several amino acids in the LRR region, pivotal for nu-
clear import and MHC class II transactivator activity (Camacho-Carvajal et al., 2004; Hake et al., 
2000). Interestingly, a mutant that lacks the N-terminal AD and P/S/T domain (CIITA-L335) is 
not able to shuttle to the nucleus. When forced to the nucleus (NLS-L335), this mutant is able to 
dominant-negatively inhibit MHC class II expression, probably by a more efficient binding to the 
MHC class II promoter, than wildtype CIITA (Camacho-Carvajal et al., 2004; Masternak et al., 
2000b; Bontron et al., 1997). Thus, the N-terminal domain, the GTPase domain and the LRR 
domain do all contribute to nuclear localization (reviewed in Krawczyk and Reith, 2006). 
As previously mentioned, additional components called enhanceosome are necessary for 
CIITA-dependent MHC class II expression. The enhanceosome components are expressed 
ubiquitously, thus regulation of MHC class II expression is dependent on a specific regulation of 
CIITA expression itself. In contrast to NLR proteins that act as PRRs, CIITA is not kept in an 
inactive state; instead CIITA apparently acquires full activity without an extra stimulus. In human, 
CIITA transcription is tightly regulated by four different promoters, pI to pIV, whereas only pI, 
INTRODUCTION 
19 
pIII and pIV are conserved in mice (Muhlethaler-Mottet et al., 1997). Each promoter was shown 
to possess unique transcription initiation sites, resulting in four different CIITA isoforms that 
differ only in their N-terminal regions. The originally described CIITA (Steimle et al., 1993) is 
transcribed from pIII. This promoter is mainly used in B cells, activated T cells and plasmacytoid 
dendritic cells (pDCs) (Krawczyk and Reith, 2006; Muhlethaler-Mottet et al., 1997). In contrast to 
pIII, pI was found to be active only in DCs and, interestingly, it results in a transcript with a 5’ 
303 bp extension that encodes a CARD-domain (CIITA-FI) (refer to figure 1.5; upper part). 
Nevertheless, this CARD domain is neither involved in cell death regulation, nor in NF-B acti-
vation. Rather, CIITA-FI is more potent to induce MHC class II expression in vitro, than CIITA-
FIII (Nickerson et al., 2001). In 2012, Zinzow-Kramer and colleagues created CIITA-pI-deficient 
mice, but could not link any essential function which is restricted to CIITA-FI, thus the function 
of the N-terminal CARD domain remains elusive (Zinzow-Kramer et al., 2012). 







































MHC class II expression is further highly inducible by the cytokine IL-4 in B cells 
(Boothby et al., 1988) and by IFN-in the majority of non-APCs (reviewed in Reith and Mach, 
2001). Responsible for the tremendous upregulation of MHC class II by IFN- is the induction 
of CIITA-FIV, which is highly inducible by IFN- (Muhlethaler-Mottet et al., 1998; Muhlethaler-
Mottet et al., 1997). Nonetheless, it has been shown that CIITA-FI is also partly induced after 
IFN- stimulation (Pai et al., 2002). Upregulation is mediated by the classical IFN- pathways, 
which requires IRF1 and STAT1 (Muhlethaler-Mottet et al., 1998). CIITA-FIV is mainly identical 
to FIII except for a small 3 kDa N-terminal truncation. A schematic overview of MHC class II 
promoter activation by CIITA and additional factors is depicted in figure 1.5. 
In contrast to MHC class II, MHC class I molecules are expressed in almost all nucleated 
cells, although differences in expression strength are detectable among different tissues (van den 
Elsen et al., 2004). Noteworthy to mention here, that MHC class I self-antigen-presentation pro-
tects cells from ‘missing-self’-mediated lysis by NK cells (Karre, 2002). Transcription of MHC 
class I genes, such as the three classical human MHC class I genes HLA-A, HLA-B and HLA-C 
and the 2-microglobulin-gene, are under the control of different promoter elements and vary 
among tissues and cell types (Johnson, 2003). Different enhancer elements are responsible for 
basal transcription or inducible transcription of MHC class I genes. The basal transcription is 
dependent on the general transcription factor TAF1 (TAFII250), whereas the inducible transcrip-
tion pathway is TAF1-independent (Howcroft et al., 2003). This transcription pathway can be 
initiated from different promoter sites, depicted in figure 1.6. 
These sites include (1) enhancer A element, (2) interferon-regulatory-response element (ISRE), 
and (3) S, X1, X2, Y-motif. Both enhancer A and ISRE element were analysed in detail by two 
studies from Gobin and co-workers showing that NF-B is able to strongly induce HLA-A and 
moderately induce HLA-B, but not other classical MHC class I loci (Gobin et al., 1998a), whereas 
ISRE mediates interferon-driven induction of classical HLA-A, HLA-B and HLA-C molecules, 
rather than non-classical HLA-E, F and G (Gobin et al., 1999). This explains the induction of 
MHC class I expression by TNF- (mediated by binding of NF-B to enhancer A) and IFN- 
(mediated by binding of IRF1 to ISRE). Notably, the S, X1, X2, Y motif is present in both MHC 
class I and MHC class II promoter regions, showing close sequence homologies (van den Elsen et 
al., 2004). In MHC class II expression, this motif was connected to CIITA-enhanceosome-
dependent activation, as described earlier in this paragraph and two early studies from Martin and 
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colleagues, as well as from Gobin and colleagues identified CIITA as an inducer of MHC class I 
promoter, strongly depending on the X1, X2, Y-box (Gobin et al., 1998b; Gobin et al., 1997; Mar-
tin et al., 1997). Moreover, the RFX-complex subunits (enhanceosome) were discussed for being 
essential for CIITA-dependent MHC class I activation. Additional factors involved in complete 
MHC class II expression such as X2BP and NF-Y were further analysed in the context of MHC 
class I activation. Their data suggest that a complex consisting of the enhanceosome, X2BP and 
NF-Y is only assembled on the X1, X2, Y motif. As a result, a similar complex as assembling at 
the MHC class II promoter is also assembled at the MHC class I promoter (Gobin et al., 2001). A 
schematic overview of the components so far identified to be involved in MHC class I activation 
is depicted in figure 1.6. 
Figure 1.6 Structural overview of the classical MHC class I promoter region 
MHC class  I  is ubiquitously expressed among a broad variety of nucleated cell  types  (driven by an 
upstream  promoter  element),  but  is  also  highly  inducible  by  NF‐B  (enhancer  A)  or  IRF‐1  (ISRE) 





The involvement of CIITA in MHC class I and II expression was further examined in CIITA 
knock-out mice (Itoh-Lindstrom et al., 1999). Although several groups reported an involvement 
of CIITA in MHC class I expression in vitro, this could not be validated in vivo. Rather, CIITA-
deficient mice did not show any difference in MHC class I surface expression in B cells (Itoh-
Lindstrom et al., 1999). Taking this into consideration, together with the fact that MHC class I 
and II pathways present peptides from distinct sources, differential mechanisms to control ex-
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pression seems plausible. Nevertheless, similarities between MHC class I and II are obvious. 
Thus, overlapping regulatory factors together with additional and unique regulatory proteins 
could perceive the difference between MHC class I and II expression. 
 
1.5 Aim of the study 
In the last decade, many NLR proteins have been characterized as receptors for pathogen associ-
ated molecular patterns (PAMPs) or host-derived danger associated molecular pattern (DAMPs) 
in host immune responses. However, additional biological activities of NLR proteins have been 
reported (reviewed in Kufer and Sansonetti, 2011). The best studied NLR protein with a non-
PRR function is the MHC class II transcriptional activator CIITA, which was reported to tightly 
control the transcription of classical MHC class II genes and its involvement in MHC class I 
transcription was also implicated in vitro (reviewed in Krawczyk and Reith, 2006). 
The aim of this thesis was to unravel the biological function of the previously uncharac-
terized NLR protein NLRC5. To this end, a thorough functional characterization of NLRC5 was 
conducted to elucidate the contribution of NLRC5 to cell-autonomous immune responses and 
MHC expression in human cells. 
In the first part of this thesis, we analysed the expression of NLRC5 in different human 
tissues and cells, including expression analyses of NLRC5 upon a variety of different immunity 
activating stimuli. We furthermore characterized the function of NLRC5 in different innate im-
mune pathways. 
In the second part, we investigated the contribution of NLRC5 to MHC transcriptional 
regulation and analysed the underlying mechanism in more detail. Moreover, we investigated the 
involvement of the different domains of NLRC5 in signalling activity, drawing connections to the 
well-studied model-NLR CIITA. 







All chemicals were purchased from Roth, Merck or Sigma-Aldrich, unless otherwise noted. 
All enzymes were purchased from Fermentas / Thermo Scientific. 
 
2.1.2 Kits 
All kits were purchased from Macherey-Nagel, unless otherwise noted. 
The human cDNA panels were purchased from Clontech, hereafter Human MTC Panel I (Cat. 
#636742), Human MTC Panel II (Cat. #636743), Human Immune System MTC Panel (Cat. 




B16F10 is a murine melanoma cell line, derived from murine BL6 melanoma cells. They were 
reported to be almost deficient in MHC class I and II surface molecule expression, but MHC 
surface expression can be induced upon different stimuli (Li et al., 1996; Gorelik et al., 1991; 
Gorelik et al., 1985).  
 
HEK293T cells 
Human embryonic kidney 293 (HEK293) cells are derived from embryonic human kidney and 
due to their easy handling, are widely used in cell biology. The HEK293T cell line is a highly 
transfectable derivative of the HEK293 cell line, which stably expresses the SV40 large T-antigen. 
HEK293T cells were purchased from ATCC (#CRL 11268). 
 
HEK‐Blue™ IFN‐/ 
HEK-Blue™ IFN-/ cells (Invivogen; Cat. #hkb-ifnab) are derived from human embryonic 
kidney 293 (HEK293) cells by stable transfection with the human STAT2 and IRF9 genes to 
obtain a fully active type I IFN signalling pathway. Furthermore, they are stably transfected with 
a secreted embryonic alkaline phosphatise (SEAP) reporter under the control of the IFN-/ 
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inducible ISG54 promoter. Stimulation of HEK-Blue™ IFN-/ cells with human type I IFN 




HeLa cells are adherent human epithelial cells transformed by human papillomavirus 18 




Primary human dermal fibroblasts were obtained by outgrowth from skin explants as previously 
described (Zigrino et al., 2001). 
 
THP‐1 cells 
THP-1 is a human acute monocyte leukemia cell line, derived from peripheral blood of a one year 
old human male with acute monocytic leukemia. THP-1 cells are non-adherent and grow in sus-
pension, but can be differentiated into adherent macrophage-like cells using phorbol esters, such 




The E.coli XL1 Blue is a non-pathogenic laboratory strain of the E.coli bacteria, which allows 
blue-white colour screening for recombinant plasmids and is an excellent host strain for routine 
cloning applications using plasmid or lambda vectors. 
Genotype:  endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 proAB+ lacIq 
Δ(lacZ)M15] hsdR17(rK- mK+) 
 
Escherichia coli DH5α 
The E.coli DH5α is a non-pathogenic laboratory strain of E.coli bacteria, commonly used for rou-
tine cloning applications. 
Genotype:  F-, lac1-, recA1, endA1, hsdR17, ∆(lacZYA-argF), U169, F80dlacZ∆M15, 
supE44, thi-1, gyrA96, relA1  





All FLAG-epitope tagged NLRC5 constructs were cloned using PCR cloning strategy with the 
indicated primer pairs. Myc-tagged NLRC5 constructs were cloned from the FLAG-tagged 
pCMV-Tag2B into myc-tagged pcDNA3.1-3xmyc-B. 
All amino acid numbers refer to the full length NLRC5 isoform 1 sequence (gene bank reference 
number 156633662). 
 












NLRC5 AA 1-1866 
K234A (Walker A mu-
tant) 


























1866  FLAG  337, 86  this study 
MYC-NLRC5  pcDNA3.1-





NLRC5 AA 1-1866 
K234A (Walker A mu-
tant) 




3xmyc-B  NLRC5 AA 1-720  MYC  /  this study 























CIITA expression plasmids in the EBV-based expression vector EBSB were previously described 
(Camacho-Carvajal et al., 2004; Hake et al., 2000; Steimle et al., 1993). 
 
Name  Vector  Insert  Tag  Reference 
CIITA-FI  EBSB-PL  CIITA isoform I  No tag 
(Camacho-Carvajal et al., 
2004; Hake et al., 2000; 
Steimle et al., 1993) 
CIITA-FIII  EBSB-PL  CIITA isoform III  No tag 
(Camacho-Carvajal et al., 
2004; Hake et al., 2000; 




CIITA isoform III FLAG this study 
GFP-CIITA  EBSB-PL  CIITA isoform III   EGFP 
(Camacho-Carvajal et al., 
2004; Hake et al., 2000; 




All Chimera constructs were cloned into the pCMV-Tag2B backbone by PCR amplificiation of 
FLAG-NLRC5 or CIITA-FIII using the indicated primer pairs. The 2xNLS constructs were am-
plified from the FLAG-tagged chimera constructs using the indicated primer pairs. 
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CIITA AA 1-163 
fused to NLRC5 AA 
110-1866 





CIITA AA 1-335 
fused to NLRC5 AA 
110-1866 
FLAG  409, 412-






CIITA AA 1-761 
fused to NLRC5 AA 
562-1866 
FLAG  409, 429-





NLRC5 AA 1-142 
fused to CIITA AA 
163-1130 






NLRC5 AA 1-142 
fused to CIITA AA 
335-1130 






NLRC5 AA 1-142 
fused to Nod1 AA 
126-953 






142 fused to Nod1 
AA 126-953 







163 fused to NLRC5 
AA 110-1866 







335 fused to NLRC5 
AA 110-1866 






NLRC5 AA 1-561 
fused to CIITA AA 
762-1133 
FLAG  421, 426-428  this study 




Name  Vector  Insert  Tag  Reference 
FLAG-NOD1 pCMV-Tag2B NOD1 wt FLAG (Kufer et al., 2008) 
FLAG-NOD2 pCMV-Tag2B NOD2 wt FLAG (Kufer et al., 2006) 
HLA-A230  pGL3-Luciferase BglI-AhaII-HLA-A2.1 
promoter fragment  No tag  (Gobin et al., 1997) 
HLA-B250  pGL3-Luciferase  AspI-AhaII HLA-B7 
promoter fragment  No tag  (Gobin et al., 1997) 
HLA-
B250”TCGCA”  pGL3-Luciferase 
X1 box mutation of 
HLA-B250, described 
as mX1 mutation 
No tag  (Gobin et al., 1998b)
IFN--luciferase / 
125 bp fragment of 
the IFN- gene with 
two ISRE sites, one 
NF-B site and an 
Jun/IRF2 site 
No tag 
kindly provided by 
AG Bowie 
IRF7-Gal4 / 
IRF7 promoter region 
fused to a Gal4 DNA-
binding domain 
No tag 
kindly provided by 
KA Fitzgerald 
ISRE-luciferase / 
5 x ISRE enhancer 
and TATA box linked 
to luciferase gene 
No tag 
kindly provided by 
KA Fitzgerald 
NF-B-luciferase NF-B reporter Ig-
luciferase 
 No tag (Munoz et al., 1994) 
pcDNA3.1-
3xmyc-B  pcDNA3.1 
3 x myc-tagged fused 
to MCS  MYC 
H. Sillje (MPI Bio-
chemistry, Martins-
ried) 
pcDNA3.1-gal  pcDNA3.1 -galactosidase  No tag  (Kufer et al., 2006) 
pCMV-Tag2B /  FLAG Stratagene 
(Catalog #211172) 
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pFR-luciferase / 
five tandem repeats of 
the yeast GAL4 bind-
ing site fused to the 









All oligonucleotides were applied from MWG Biotech. 
 
Primer  Application  Primer №  Sequence 
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GAPDH_fwd  RT-PCR  1  GGTATCGTGGAAGGACTCAT
GAC 
GAPDH_rev  RT-PCR  2  ATGCCAGTGAGCTTCCCGTTC
AG 
hGAPDH_RT_fwd  qRT-PCR  305 CAACGACCACTTTGTCAAGC 
hGAPDH_RT_rev  qRT-PCR  306  TCTTCCTCTTGTGCTCTTGC 
HLA-B_fwd  qRT-PCR  369  CTACCCTGCGGAGATCA 
HLA-B_rev  qRT-PCR  370  ACAGCCAGGCCAGCAACA 
hRANTES_ep_fwd  RT-PCR  259 
ATGAAGGTCTCCGCGGCACG
CCT (published in Matsukura et al., 
1998) 
hRANTES_ep_rev  RT-PCR  260  CTAGCTCATCTCCAAAGAGTT
G (published in Matsukura et al., 1998) 























































NLRC5_I3_fwd  Detection of NLRC5 iso-
form 3 expression  107 
AGGCTGTGGGCAGATAGAG
A 
NLRC5_iso3_rev  Detection of NLRC5 iso-
form 3 expression  271 ACCAGGCATCCCCAGC 
NLRC5_iso4_fwd  Detection of NLRC5 iso-
form 4 expression  272  TTTGCACTTCAGATCCAACG 
NLRC5_iso4_rev  Detection of NLRC5 iso-
form 4 expression  273 GATCAAGCAAACCGGAGATG
NLRC5_K234A_fw
d 












NLRC5_LRR_fwd  Cloning of NLRC5 LRR  336 GCGCGATATCGGTGCCAAGC
AGGCTGCT 
NLRC5_M_fwd  qRT-PCR  109  CTGCAGCCAAGTTCTTAGGG 
NLRC5_M_rev  qRT-PCR  110  TCAGCTGAGGGAGTTGAGGT













































Seq_NLRC5_1  Sequencing of NLRC5  97  GGCAGCCCCACGCCTTC 
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Seq_NLRC5_2  Sequencing of NLRC5  98  CAATGGGACCCTCCTGCCTG 
Seq_NLRC5_3  Sequencing of NLRC5  99  CACAGGCCCTGGGCACCAG 
Seq_NLRC5_4  Sequencing of NLRC5  100  CTGGATTTTGATGGCTGTCCC
CTG 
Seq_NLRC5_5  Sequencing of NLRC5  101  GTGACGGCCAGAGGAAAGG
G 
Seq_NLRC5_6  Sequencing of NLRC5  102  GAAGCTGCCACCTCGGTCAC 
Seq_NLRC5_7  Sequencing of NLRC5  103  GCTGCAGCTGAGCCAGACGG 
Seq_NLRC5_8  Sequencing of NLRC5  104  CTTCCGGCCAGAGCACGTGT
C 
Seq_NLRC5_9  Sequencing of NLRC5  105  CTGAAGACATTTCGGCTGAC
CTCCAG 





All siRNAs were applied from Qiagen. 
 
Gene  Name  Number  Target 
No Target  All Stars  SI1027281  No target 
NLRC5  Hs_NLRC5_1  SI04143510  CAGGGTTCTCTCCCTGTTAGA 
NLRC5  Hs_NLRC5_4  SI04300814  CTGCTTATCTTTGATGGGCTA
TBK1 siTBK1 
published in 
(Sharma et al., 
2003b) 
GCGGCAGAGTTAGGTGAA 
TLR3 siTLR3 published in (Li et al., 2005) 
GGTATAGCCAGCTAACTAG 





All antibodies were diluted in 5 % milk powder in PBS. 
 
Antigen  Source  Clone  Dilution  Reference 
-actin mouse mAB C4 WB 1:10000 Santa Cruz Biotechnology 
(sc-47778) 
c-MYC rabbit pAB A-14 WB 1:1000 Santa Cruz Biotechnology (sc-789) 




GAPDH rabbit pAB FL355 WB 1:1000 
Santa Cruz Biotechnology 
(sc-25778) 
GFP mouse mAB 7.1/13.1 WB 1:2000 Roche (Cat. No. 11-814-460-001) 
HLA-B/C mouse mAB / WB 1:3000 gift from Anne Halenius 
HLA-DR mouse mAB 520B WB 1:200 
Santa Cruz Biotechnology 
(sc-69673) 
MYC mouse mAB 9E10 IF 1:1000 Roche (Cat. No. M4439) 
NLRC5 3H8 rat mAB 3H8 WB 1:5 (Neerincx et al., 2010) 
NLRC5 5D4 rat mAB 5D4 WB 1:5 (Neerincx et al., 2010) 
NOD1 rat mAB 2A10 WB 1:100 (Kufer et al., 2008) 
NOD2 rat mAB 7E11 WB 1:100 (Kufer et al., 2006) 
TBK1 mouse mAB 108A429 WB 1:1000 
Santa Cruz Biotechnology 
(sc-52957) 
TLR3 goat pAB N-14 WB 1:1000 
Santa Cruz Biotechnology 
(sc-8691) 
Tubulin mouse mAB 4G5 WB 1:1000 Sigma-Aldrich (T7816) 
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Secondary Antibodies 
All secondary antibodies were diluted 1:4000 in 5 % milk powder in PBS. 
 
Antigen  Reference 
Goat anti-Mouse IgG (H+L) – HRP conjugated Bio-Rad (170-6516) 
Goat anti-Rabbit IgG (H+L) – HRP conjugated Bio-Rad (170-6515) 
Goat anti-Rat IgG + IgM (H+L) – HRP conjugated Santa Cruz Biotechnology (sc-789) 
POD-conjugated Goat anti-Mouse LC specific Dianova (115-035-174) 




Antigen  Source  Clone  Reference 
anti-H-2kb mouse mAB AF6-88.5 BD Pharmingen™ (#553568) 
anti-IA/IE-Alexa647 mouse mAB 2G9 BD Pharmingen™ (#885893) 
HLA-ABC-APC  mouse mAB  G46-2.6 BD Pharmingen™ (#562006) 
IgG control-APC mouse mAB MOPC-21 BD Pharmingen™ (#555751) 




Antigen  Source  Clone  Reference 
FLAG  mouse mAB  M2  Sigma-Aldrich (A2220) 
MYC  mouse mAB  9E10  Santa Cruz Biotechnology (sc-40) 





Biofuge pico Heraeus 
CellR Olympus 
Centrifuge 5415R Eppendorf 
Centrifuge 5418 Eppendorf 
Centro XS3 LB960 Luminometer Berthold Technologies 
FACSCanto Flow Cytometer BD Biosciences 
Gel Electrophoresis System Bio-Rad-Laboratories 
Incubator Heraeus 
iQ5™ cycler (qRT-PCR cycler) Bio-Rad-Laboratories 
LAS-4000 Luminescent Image Analyser Fujifilm 
Microcentrifuge Roth 
Multifuge 4KR Heraeus 
Multipette plus dispenser Eppendorf  
Nano Photometer™  Implen GmBH 
Neubauer Counting Chamber Improved Labor Optik 
Nunc-Immuno Wash 12 Nunc 
Pipetboy acu Integra Biosciences 
Plate Reader bt 2 Anthos 
Primus Thermocycler MWG Biotech 
PS-M3D Orbital Shaker Grant-bio 
Research pro Multichannel Pipettes Eppendorf 
roller mixer srt6 stuart 
Steri-Cycle CO2 Incubator, Model 381 Thermo Forma 
Sterile Bench Heraeus 
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Thermomixer comfort Eppendorf 
TRANS BLOT SD, Semi-Dry Transfer Cell Bio-Rad Laboratories 





Adobe Acrobat 9 Professional Adobe Systems Incorporated 
Adobe Illustrator CS5 Adobe 
Adobe Photoshop CS5 Adobe 
Bio-Rad iQ5 version 2.0 Bio-Rad Laboratories 
CellR Software Olympus 
CellQuest software BD Biosciences 
Endnote X Thomson Reuters 
FACSDiva BD Biosciences 
ImageJ (Schneider et al., 2012) 
Imagereader LAS-4000 Fujifilm 
Microwin 2000 Berthold Technologies 
Microsoft Office 2003 Microsoft 
 
 







Mouse melanoma B16F10, HEK293T cells and HeLa cells were cultivated at 37 °C with 5 % 
CO2 in Dulbecco’s Modified Eagle Medium (DMEM, Biochrom AG)) containing 10 % heat-
inactivated Fetal Bovine Serum (FBS, Biowest) and penicillin/streptomycin (100 IU/ml and 100 
mg/ml, respectively) (P/S) (Biochrom AG) under humidified conditions. 
HEK-Blue™ IFN-/cellswere grown at 37 °C with 5 % CO2 in DMEM containing 10 % 
FBS, penicillin/streptomycin, 30 µg/ml blasticidine (Invivogen) and 100 µg/ml zeocin™ (Invi-
vogen) under humidified conditions. 
Primary human dermal fibroblasts (hFibr) were maintained at 37 °C with 5 % CO2 in DMEM 
containing 10 % FBS and P/S under humidified conditions. 
THP-1 cells were grown at 37 °C with 5 % CO2 in Roswell Park Memorial Institute 1640 Me-
dium (RPMI-1640, Biochrom AG) containing 10 % FBS and P/S under humidified conditions. 
Cells were continuously tested for mycoplasma contamination. 
 
Stimulation and Infection of Cells 
5x105 THP-1 cells were seeded in 6 well dishes either directly before stimulation, or 5x105 cells 
were seeded 24 h prior stimulation and differentiated with 100 nM PMA for 24 h. Stimulation 
was performed using 50 ng/ml tumor necrosis factor (TNF), 1 µM muramyl dipeptide (MDP), 50 
ng/ml lipopolysaccharide (LPS), 0.5 µM phorbol 12-myristate 13-acetat (PMA), 100 ng/ml 
Pam3CSK or 100 µg/ml poly(I:C) for 6 to 24 h as indicated in the specific experiments. For in-
fection of THP-1 cells with Sendai Virus (SeV, Charles River Laboratories), cells were seeded as 
for stimulation and infected with 80 hemagglutination units (HAU) / ml. 
HeLa cells were seeded in 6 well dishes 16 to 18 h before stimulation to a confluence of about 60 
%. Stimulation and infection was performed as described for THP-1 cells using 160 HAU / ml 
for 16 to 24 h. 
 
Transient DNA transfection 
For transient DNA transfection of adherent cells, cells were seeded in DMEM containing FBS 
and P/S in an adequate cell culture dish 24 h prior transfection in order to reach a cell density of 
about 50 to 70 %. To obtain an increasing expression time of the protein of interest (48 h to 72 
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h), cell density was reduced to 30 to 50 %. For transfection, Lipofectamine2000 (Invitrogen), 
FuGene6 (Roche) or XtremeGene9 (Roche) was used in a ratio of 1:3 (DNA : transfection re-
agent) in DMEM without supplements as described in the manufacturers’ protocol. The ready-
to-transfect transfection mixes were incubated 20 to 30 min prior transfection, to allow transfec-
tion complex formation. 
For HeLa cell transfection, 6 h after transfection, the transfection medium was replaced by 
DMEM containing FBS and P/S. 
For HEK293T cells, a medium change was conducted 16 to 24 h after transfection. 
 
siRNA transfection 
For siRNA transfection in THP-1 cells, 2x105 cells were seeded into 24 well format in 500 µl 
RPMI containing FBS and P/S and differentiated for at least 24 h using 100 nM PMA. Shortly 
before siRNA transfection, the medium was replaced by 100 µl RPMI containing FBS and P/S. 
For transfection, 100 nM siRNA and 6 µl HiPerfect were diluted in 100 µl RPMI without sup-
plements. The transfection mix was incubated 5 to 10 min at RT before added to the cells. 6 h 
after transfection, another 400 µl complete RPMI medium was added to the cells. One day after 
transfection, the medium was changed. 72 h after siRNA transfection, cells were stimulated and 
further analyses were performed as indicated. 
For siRNA transfection in HeLa and hFibr, 5x104 cells were seeded in 24 well format in 500 µl 
DMEM containing FBS and P/S one day prior transfection. siRNA transfection was performed 
in 100 µl DMEM without supplements containing 10 nM siRNA and 3 µl HiPerfect, as described 
in the manufacturer’s protocol. 24 h after siRNA transfection, the medium was changed by 
DMEM containing FBS and P/S. siRNA silencing was performed for 72 h, unless specified oth-
erwise. After 72 h, cells were stimulated with 100 µg/ml poly(I:C) or infected with 130 HAU/ml 
SeV for 16 to 18 h. 
For further analyses, RNA was extracted by pooling three 24 well wells. 
 
Luciferase reporter assay 
For a cell based luciferase assay in 96 well format, 3x104 cells per well were seeded in DMEM 
containing FBS and P/S about 4 to 6 h prior transfection. For NF-B pathway activation, 13 ng 
luciferase reporter construct, for IRF7 pathway activation, 3 ng of IRF7-Gal4 together with 40 ng 
pFR-luciferase was transfected and for IFN-ISRE and MHC class I and II pathway activation, 
20 ng luciferase reporter construct was transfected together with 10 ng of -galactosidase plasmid 
as well as the indicated amount of plasmid of interest per well. For equal transfection conditions, 
the DNA amount was adjusted to 50 ng or 100 ng per well. The transfection was performed in 
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20 µl DMEM without supplements and 0.2 µl FuGene6 or XtremeGene (in case of 100 ng of 
total plasmid, 0.4 µl FuGene6 or XtremeGene) per well. The transfection mix was incubated for 
20 min prior transfection. The luciferase readout was performed 20 to 24 h after transfection 
(Zurek et al., 2011). 
For activated luciferase reporter assays, cells were infected with SeV, using 130 HAU/ml 18 h 
prior luciferase readout. 
For the readout, cells were lysed in 100 µl luciferase lysis buffer per well. Subsequently, 50 µl of 
cell lysate was used to determine luciferase activity using 100 µl luciferase readout buffer and the 
remaining 50 µl cell lysate was mixed with 100 µl ONPG development buffer to determine -
galactosidase activity. The luciferase readout was performed using a Centro XS3 LB960 Lumi-
nometer (Berthold Technologies). The -galactosidase readout was performed using an anthos bt 
2 plate reader. 
Luciferase activity was normalized to -galactosidase expression and mean and standard deviation 
were calculated from triplicates.  
 
Luciferase lysis buffer: 25 mM TRIS pH 8.0, 8 mM MgCl2, 15 % glycerol, 1 % 
Triton X-100, stored at 4 °C 
Luciferase read out buffer: Luciferase lysis buffer supplemented with 0.54 µg/ml D-
Luciferin and 1.33 mM ATP, freshly prepared 
ONPG dilution buffer: 60 mM Na2HPO4x2H2O, 40 mM NaH2PO4, 10 mM KCl, 1 
mM MgSO4x7H2O, pH 7.0 
ONPG stock solution: 4 mg/ml ONPG in ONPG dilution buffer, stored at 4 °C 
ONPG development buffer: 1:4 dilution of ONPG stock solution in ONPG dilution 
buffer, freshly prepared 
 
HEK‐IFN‐ reporter assay 
For detection of type I interferons, 3x104 HEK-Blue™ IFN-/ cells were seeded in 20 µl of 
DMEM containing 10 % FBS and P/S under humidified conditions in 96 well plate format. 
These cells were stably transfected with the human STAT2 and IRF9 to maintain a completely 
functional type I IFN signalling pathway and were further transfected with a SEAP reporter gene 
under the control of the IFN-α/β inducible ISG54 promoter. Directly after seeding of the cells, 
the type I IFN supernatant was added to the cells and the cells were incubated for 16 to 24 h. 
After incubation, the levels of secreted SEAP were determined using QUANTI-Blue™ SEAP-
detection medium. For that purpose, 20 to 50 µl of HEK-Blue™ IFN-/ cell supernatant were 
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incubated with 180 to 150 µl of QUANTI-Blue™ SEAP-detection medium and incubated at 37 
°C up to 1 h. SEAP activity was measured at 620 nm. All assays were performed in triplicates. 
 




To accomplish indirect immunofluorescence microscopy, HeLa cells were seeded in 24 well for-
mat on sterilized glass coverslips in 500 µl DMEM containing FBS and P/S one day before trans-
fection to a confluence of about 40 to 50 %. Shortly before transfection, the medium was re-
placed by 500 µl DMEM containing FBS but no antibiotics. Cells were transiently transfected 
with 1 µg of indicated plasmid using Lipofectamine2000 as described in the manufacturer’s pro-
tocol. 6 h after transfection, the transfection medium was replaced by DMEM containing FBS 
and P/S. After 24 h, cells were either treated with 50 nM Leptomycin B (LepB) for 4h or left 
untreated. Subsequently, cells were fixed using 3 % paraformaldehyde (PFA) in PBS for 5 to 10 
min. After fixation, cells were washed three times using PBS and then permeabilized for 5 min 
using 0.5 % Triton X100 in cold PBS. After three additional washing steps with PBS, cells were 
incubated in 3 % BSA in PBS to block unspecific protein interactions. Antibody staining was 
performed for 1h at RT using either anti-myc antibody or anti-FLAG M2 antibody, diluted 
1:1000 and 1:8000, respectively. For visualization of anti-c-myc or anti-FLAG M2 antibody, sam-
ples were incubated with Alexa488-conjugated anti-mouse antibody for an additional hour at RT. 
Finally, unbound antibody was removed by three additional washing steps and cells were 
mounted in Prolong® Gold Antifade Reagent (Invitrogen). Image acquisition was performed 
using a CellR microscope and processed using ImageJ (Schneider et al., 2012). 
 
0.5 % Triton:    1x PBS + 0.5 % Triton X-100 
3 % PFA Solution:   1x PBS + 3 % (v/v) PFA 
3 % BSA:    1x PBS + 3 % BSA 
PBS (10x): 1,37 M NaCl, 26.82 mM KCl, 80.9 mM Na2HPO4x2H2O, 
17.63 mM KH2PO4, pH 7.4  





For production of chemical competent bacteria, a 500 ml LB medium culture of DH5bacteria 
inoculated from a single bacterial colony was incubated over night at 37 °C. This culture was sub-
sequently used to inoculate a second LB bacterial culture, growing at 20 °C and shaking at 200 
rpm until the bacterial culture has reached an OD600 of 0.3 to 0.6. Next, the culture was chilled on 
ice for about 10 min and pelleted at 4 °C and subsequently washed with 150 ml of cold transfor-
mation buffer. Finally, the culture was centrifuged again and the pellet was resuspended in 40 ml 
transformation buffer and 3 ml DMSO and aliquots of about 500 µl were frozen in liquid nitro-
gen and stored at -80 °C. 
 
LB medium: 10 g Tryptone, 10 g NaCl, 5 g Yeast Extract add 1 L H2O, auto-
claved 
LB agar plates: 15 g Agar Powder added to 1 L LB medium, supplemented with 
antibiotics (50 µg/ml Kanamycin, 100 µg/ml Ampicillin, 4 °C) 
Transformation buffer: 15 mM CaCl2, 250 mM KCl, 10 mM PIPES, 55 mM 
MnCL2x4H2O, pH 6.7, sterile filtrated 
 
Heat‐shock transformation of chemical competent bacteria 
Chemical competent bacteria E.coli DH5 were carefully thawn on ice. For retransformation of 
plasmid DNA, 100 ng of the plasmid of interest was added to 50 µl of chemically competent 
bacteria and incubated for 30 min on ice. After 30 min, a heat-shock was performed for 90 sec at 
42 °C followed by a short incubation on ice. Next, 250 µl of LB medium was added to the 50 µl 
transformed bacteria sample. Depending on the resistance marker of the plasmid, the trans-
formed bacteria were incubated for one hour at 37 °C shaking prior plating (for kanamycin) or 
were directly plated on LB agar plates (for ampicillin) containing either 50 µg / ml kanamycin or 
100 µg / ml ampicillin. 
 
Isolation of plasmid DNA from E.coli DH5a 
For plasmid isolation from E.coli, bacteria were either cultured in 5 ml LB containing antibiotics 
(for Miniprep) or in 100 ml LB containing antibiotics (for Maxiprep) over night at 37 °C shaking . 
The next day, bacteria were pelleted for 15 min at 4000 x g at 4 °C. Isolation of plasmid DNA 
was performed using the NucleoBond PC20 (Macherey-Nagel) or PC500 (Macherey-Nagel) 
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plasmid preparation kit as described in the manufacturer’s protocol. The plasmid DNA pellet was 
resuspended in 100 to 200 µl 10 mM TRIS pH 8. The plasmid DNA concentration and purity 
was determined using a nanodrop photometer measuring absorption of 260 and 280 nm. 
 
Isolation of RNA from human cells 
RNA was isolated from human cells using the RNeasy Mini Kit (Qiagen) according to the manu-
facturers’ protocol. RNA was eluted with RNase free water. RNA concentration and purity was 
measured using a nanodrop photometer measuring absorbance at 260 to 280 nm. 
 
Reverse transcription of RNA 
1 µg of isolated RNA was reverse transcribed into cDNA using the RevertAid First Strand 
























   25-30x 
   (depending on the 






cDNA  50 to 100 ng 
Taq Buffer (+KCl; -MgCl2) (10 x)  5 µl 
MgCl2 (25 mM)  4 µl 
dNTPs (10 mM)  2 µl 
Taq DNA Polymerase (5 u/µl)  0.5 µl 
primer fwd  10 pmol 
primer rev  10 pmol 
H2O  up to 50 µl 
Time  Temperature 
1 min  94 °C 
15 sec  94 °C 
30 sec  55 °C 
30 sec  72 °C 
5 min  72 °C 
∞  4 °C 
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For cloning of NLRC5 and CIITA fusion proteins, the fragments of interest was amplified by 
PCR from FLAG-NLRC5 or CIITA-FIII with the primers indicated above, using the 
2xPhusion® High-Fidelity PCR Master Mix (Finnzymes) as described in the manufacturer’s pro-
tocol. Subsequently, the PCR product was digested using the appropriated restriction enzymes 
for 4 h at 37 °C. The digested PCR fragments were purified using a 1 to 2 % preparation gel with 
further gel extraction using the ExtractIT-Kit (Macherey-Nagel). 
 
Site‐directed mutagenesis 
Point mutation introduction was performed by PCR using the QuikChange™ Site-Directed 


























plasmid DNA (100 ng/µl) 2.5 µl 
2x Phusion™ Master Mix  25 µl 
primer fwd (10 pmol/µl) 1 µl 
primer rev (10 pmol/µl) 1 µl 
H2O up to 50µl 
Time  Temperature 
30 sec  98 °C 
10 sec  98 °C 
30 sec  65 °C 
3 min  72 °C 
5 min  72 °C 
∞  4 °C 
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To digest plasmid DNA, 1.5 µl DpnI (+6 µl Buffer + 3.5 µl H2O) was added to the PCR mix and 
incubated at 37 °C for 2 h. Subsequently, 5 µl PCR sample was transformed into 50 µl of chemi-
cal competent bacteria. 
 
Restriction digestion of plasmid DNA 
For restriction of plasmid DNA, 1 to 2 µg of plasmid DNA was digested using 5 u of the appro-
priate restriction enzyme for 4 h at 37 °C. Buffer and temperature conditions were adjusted ac-
cording to the specific enzyme. Simultaneous digestion with two restriction enzymes was per-




DNA fragments were separated and analysed by agarose gel electrophoresis using 1 to 2 % aga-
rose dissolved by boiling in 1 x TBE. The liquid agarose was poured into a gel and mixed with 0.5 
µg/ml ethidium bromide. Samples were dosed with 10 x DNA loading buffer or 6 x low range 
DNA loading buffer. GeneRuler Low Range DNA Ladder (Fermentas; Cat. Nr. SM1191) or 
Lambda Hind III/phiX Hae III Marker (Roth; CP49) were used as standards. The gel was run at 
80 V and bands were detected under UV light. 
 
10 x TBE (TRIS-borate EDTA):  0.89 M TRIS, 0.89 M boric acid, 20 mM Na2EDTA 
pH 8.0 
  The working solution was prepared by 1:10 dilution 
in ddH2O and addition of 20 % methanol. 




Digested DNA fragments were ligated using the Rapid DNA Ligation Kit (Fermentas) according 




Quantitative real-time PCR (qRT-PCR) was performed using a Bio-Rad iQ™ cycler and the iQ 
™ SYBR® Green Supermix. For each qRT-PCR reaction, 50 ng cDNA in a volume of 25 µl 
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PCR Mix was used. For qRT-PCR reactions of human cDNA panel, 1 µl of stock cDNA was 
used per qRT-PCR reaction. 
 
The reaction was prepared as follows: 
 
Reagent  Volume/Concentration 
2x iQ ™ SYBR® Green Supermix  12.5 µl 
primer fwd  0.07 µl / 7.5 pmol 
primer rev  0.07 µl / 7.5 pmol 
H2O  add 20 µl 
 
The indicated cDNA amount in a volume of 5 µl ddH2O was added to each reaction. Reaction 
mixes were prepared on ice and drops were collected by centrifugation before starting the reac-
tion. The PCR was performed in 96 well PCR plate format under following conditions: 
 
Temperature  Time   
95 °C  3 min  1 x 
95 °C  15 sec 
60 °C  1 min  40 x 
55 °C  30 sec  81 x 










Proteins were separated as previously described (Laemmli, 1970). Separation was performed us-
ing either a 7.5 % or 10 % TRIS-buffered SDS-Polyacrylamide-Gel. Samples were dosed with 6 x 
Laemmli loading buffer containing -mercaptoethanol and boiled 5 min at 95 °C prior loading. 
Samples were run at 120 to 180 V until the dye front completely drained off the gel. 
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6 x Laemmli buffer: 7 ml 0.5 M Tris/0.4 % SDS pH 6.8, 3 ml glycerol, 1 g SDS, 
bromophenole blue, 60 µl -mercaptoethanol added di-
rectly before use 
Separation gel: 2.1 ml ddH2O, 2.5 ml acrylamide (40 %), 5 ml 0.5 M 
TRIS/0.4 % SDS pH 8.8, 25 µl TEMED, 50 µl APS 
Stacking gel: 4.5 ml ddH2O, 650 µl acrylamide (40 %), 1.25 ml 0.5 M 
TRIS/0.4 % SDS pH 6.8, 25 µl TEMED, 50 µl APS 
SDS-PAGE running buffer (10 x): 250 mM TRIS, 1.92 M glycine, 34.67 mM SDS; 
working solution was prepared by 1:10 dilution in ddH2O. 
 
Separated proteins were transferred on nitrocellulose membrane by semi-dry western blotting at 
15 V for 50 min. Blot efficiency was controlled by Ponceau-S staining. 
 
PBS-T     1x PBS + 0.05 % Tween20 
Ponceau-S solution:   0.2 % Ponceau S, 3 % acetic acid 
Transfer buffer (10 x):   250 mM TRIS, 1.92 mM glycine 
The working solution was prepared by 1:10 dilution in 
ddH2O and addition of 20 % methanol. 
 
Membranes were blocked using 5 % milk powder in PBS to avoid unspecific binding of antibod-
ies. 
All primary antibodies were diluted in 5 % milk powder in PBS and incubated for at least 1 h at 
RT or over night incubation at 4 °C. 
After primary antibody incubation, the membrane was washed 3 times with PBS containing 0.05 
% Tween20. Secondary antibodies were diluted in 5 % milk powder in PBS and incubated for 1 h 
at RT. Proteins were detected using SuperSignal West Pico Chemiluminescent Substrate or 
Femto maximum Sensitivity Substrate (Thermo Scientific). Signals were recorded on an elec-
tronic imaging system (LAS4000, Fujifilm).  
 
Co‐Immunoprecipitation 
For Co-Immunoprecipitation of overexpressed proteins, HEK293T cells were seeded in 10 cm 
dishes one day prior transfection. Cells were transiently transfected with 1 to 3 µg of each plas-
mid as indicated using Lipofectamine2000 or FuGENE6, according to the manufacturers’ proto-
col. 24 h after transfection, cells were lysed in NP40 or RIPA lysis buffer containing phosphate 
inhibitors (20 µM -glycerophosphate, 5 mM NaF, 100 µM Na3VO4), protease inhibitors (1 tablet 
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for 50 ml lysis buffer) and 2 mM EDTA. The lysates were incubated on ice for 20 min and sub-
sequently cleared by centrifugation at 14.000 x g and 4 °C. 50µl of supernatant was stored for 
input samples and remaining supernatant was utilized directly for immunoprecipitation using 20 
µl anti-FLAG M2 (Sigma-Aldrich) or 20 µl anti-myc beads (Santa Cruz) for 4 h at 4 °C on an 
end-to-end rotator. After precipitation, beads were washed 5 times using NP40 or RIPA lysis 
buffer with additives. The washed beads were dosed with equal amounts of 2 x Laemmli buffer. 
For SDS-PAGE analysis, 15 µl input or 10 µl of IP were loaded. 
 
NP40 lysis buffer:   150 mM NaCl, 50 mM TRIS pH 7.4, 1 % NP40, 4 °C 
     freshly add EDTA, protease and phosphate inhibitors 
RIPA lysis buffer: 150 mM NaCl, 50 mM TRIS pH7.4, 1 % Triton X-100, 0.1 
% SDS, 0.5 % deoxycholic acid sodium salt, 4°C 
 freshly add EDTA, protease and phosphate inhibitors 
 
Subcellular fractionation of HeLa cells 
For stimulation of HeLa cells, 5x106 cells were seeded in a 10 cm dish one day before stimulation. 
For activation of TLR3, cells were stimulated with 100 µg/ml poly(I:C) for 24 h. After 24 h, the 
medium was changed and nuclear export was blocked using 50 nM Leptomycin B for 4 h. Subse-
quently, subcellular fractionation was performed using the Qproteome Compartment Kit (Qiagen 
Cat. # 37502) as described in the manufacturer’s protocol. 
The cytosolic and the nuclear fraction were directly used for IP using 20 µl anti-NLRC5 3H8 
antibody-coupled protein G sepharose beads (incubation of 70 µl protein G sepharose beads 
with 1400 µl anti-NLRC5 3H8 antibody hybridoma supernatant over night). Beads were proc-
essed as described in Co-Immunoprecipitation part. 
 
Cytokine Profiling and ELISA 
For cytokine profiling, Proteome Profiler Human Cytokine Array Panel A kit from R & D Sys-
tems (Catalog Number ARY005) was used. Quantification was performed by recording the signal 
on a LAS4000 ECL camera system and densitometric quantification to the internal controls after 
background subtraction (ImageJ). 
ELISA for IFN-, RANTES, and IP-10 was performed using a MultiAnalyte ELISArray kit from 
SABiosciences (MEH-007A) according to the manufacturer’s instructions. 
Secretion of CCL5/RANTES from human cells was measured using the DuoSet ELISA Devel-
opment Kit from R & D Systems (Catalog Number DY278), according to the manufacturer’s 
protocol.  
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Flow cytometry 
For FACS analysis of THP-1 cells, cells were seeded in 24 well format and siRNA knock-down 
was performed as previously described. For flow cytometry preparation, cells were washed and 
trypsinized for 15 min. Subsequently, 2x105 were transferred to a 96 well plate and washed two 
times using PBS supplemented with 0.1 % FBS. HLA-A/B/C or IgG1 control staining was per-
formed in 20 µl 2 % BSA in PBS supplemented with 3 µl FACS antibody for 45 min on ice. After 
incubation, cells were washed two additional times to remove unbound antibody residues. Subse-
quently, cells were fixed in 1 % PFA in PBS for 30 min on ice. After two additional washing steps 
with PBS containing 0.1 % FBS, cells can be directly analysed or stored at 4 °C up to one week. 
Samples were analysed using a FACSCanto Flow Cytometer and analysed with FACSDiva. 
B16F10 cells were transfected in 12 well plates with EBSB-GFP-NLRC5 or CIITA constructs 
and selected with antibiotics for 4 weeks. FACS analysis was performed as previously described 
(Steimle et al., 1993). Cells were stained for MHC class II expression with Alexa Fluor 647-
coupled anti-IA/IE mAB 2G9 (BD Biosciences), for MHC class I expression with biotinylated 
anti H-2kb Ab AF6-88.5 (BD Biosciences), followed by secondary staining with Streptavidin-
allophycocyanin (BD Biosciences), or appropriate controls. Cells were analysed on a FACSCanto 










Sequence comparisons of NLRC5 show the same overall multidomain architecture composed of 
effector, NACHT, winged helix, superhelical and leucine-rich repeat (LRR) domains which are 
found in all other human NLRs. Differences exist in the type of effector domain and the signifi-
cantly longer LRR receptor domain. The NLRC5 effector domain (residues 1–101) is composed 
of five -helices and shows no sequence homology to CARD or PYD domains. This indicates 
that the NLRC5 effector domain although structurally similar to CARD and PYD domains fea-
tures a different interface. The NACHT domain obtains all typical features important for nucleo-
tide hydrolysis followed by a winged helix domain and a superhelical domain. Thus, NLRC5 is a 
typical Apaf-like ATPase likely capable of ATP hydrolysis which is required for conformational 
changes leading to activation. The LRR domain in NLRC5 differs from other LRRs in respect to 
its length of more than 1000 residues. Structurally, leucine-rich repeats of that length should form 
more than a full LRR circle, resulting in a LRR helix (personal communication R. Schwarzen-
bacher). A model is depicted in figure 3.1 A.  
 
3.1.2 Expression and Induction of NLRC5 
To get a first insight into the role of NLRC5, we analysed the overall expression of NLRC5 in 
different human cells and tissues using qRT-PCR. In line with available microarray data 
(www.biogps.org), we detected highest expression of NLRC5 in cells of the hematopoietic com-
partment, in both CD4+ and CD8+ T cells, and to a lesser extent in macrophages (CD14+). In 
tissue-derived cDNA, highest expression was observed in lymph nodes, spleen, bone marrow and 
tonsils (Figure 3.1 B). 
Accordingly, we found high amounts of NLRC5 in cell lines of thymoid (Jurkat) and myeloid 
(THP-1) origin, whereas other cells lines, derived from human embryonic kidney (HEK293T) 
and colon (CaCo2) only displayed marginal expression (Figure 3.1 C). 
During the cloning of the NLRC5 open reading frame from a human leukocyte cDNA li-
brary, we could obtain different splice variants, of which five of them were already contained in 
databases (www.uniprot.org). Interestingly, the different variants all share the common 5’ region 
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encoding the effector domain and the central NACHT domain, but differed in the length of the 
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cleotide‐binding  domain  (NACHT)  and  leucine‐rich  repeats  (LRR)  domain  is  highlighted  with 
white/grey  boxes.  The  italic  numbers  refer  to  amino  acid  numbers.  Uniprot  database 
(www.uniprot.org) accession number is indicated on the left. 
E) RT‐PCR analysis of the indicated tissue samples and cell types using isoform specific primer pairs. 
NLRC5 wildtype (also termed full  length or  isoform 1) expression,  isoform 3 expression and  isoform 






As already mentioned, the LRR region of NLRC5 is unusually long, and modelling indi-
cated a large helical conformation rather than the typical horseshoe structure of other NLRs. For 
other NLR proteins like NOD1 and NOD2, it has been shown, that activation by an elicitor is 
completely based on the presence of the LRR region (Girardin et al., 2005; Tanabe et al., 2004), 
and to date, there is some evidence for a direct interaction between elicitor and LRR in the case 
of both NOD1 and NOD2 (Grimes et al., 2012; Mo et al., 2012; Laroui et al., 2011). Thus, differ-
ent truncated versions of the LRRs might give rise not only to different elicitor sensing specifici-
ties of NLRC5 but might also change the LRR domain from the helical to a classical horseshoe-
like structure found in other LRRs. Of note, isoform 3 lacking the whole LRR region was the 
prevalent cDNA obtained. Sequence analysis revealed that a differential splicing of exon 5 leads 
to a premature stop codon introduction. Another cDNA sequence we obtained (isoform 4) is 
almost identical to full length NLRC5, except lacking exon 25, which leads to a deletion of the 
amino acids 1221 to 1249. To elucidate the presence of these splice variants in different tissues, 
we designed a primer pair allowing the specific amplification of isoform 3. Moreover, another 
primer pair was used to detect the deletion of exon 25 present in isoform 4 and also 5. Both 
primer pairs were able to specifically amplify the corresponding isoforms as shown by PCR using 
plasmids containing full-length or NLRC5 isoform DNA. Analysis of different tissues with high 
expression of NLRC5 full-length (Figure 3.1 B) revealed NLRC5 isoform 3 expression in CD4+, 
CD8+ cells, lymph nodes and to a lesser extend in colon (Figure 3.1 C). However, expression of 
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isoform 4/5 was detected only at very low levels in CD4+ cells, lymph node and colon and 
slightly stronger in CD8+ cells. Similar to full-length NLRC5, also isoform 3 and isoform 4/5 
were absent in muscle cells. In HeLa and THP-1 cells that strongly express NLRC5 full-length, 
NLRC5 isoform 3 was not robustly detectable; however isoform 4/5 was expressed at low levels 
in THP-1 cells (Figure 3.1 E). 
Expression of many NLRs is induced by many PAMPs and inflammatory cytokines. 
NOD2 expression, for example, is upregulated by bacterial challenge, single-stranded RNA and 
IFN-(Sabbah et al., 2009; Oh et al., 2005; Rosenstiel et al., 2003). Furthermore, it was recently 
shown that NF-B-mediated signalling is a prerequisite of NLRP3 activation by inducing NLRP3 
expression (Bauernfeind et al., 2009). We therefore ask, whether the expression of NLRC5 might 
also be influenced by PAMP stimulation and/or inflammatory mediators. We could previously 
show, that NLRC5 is robustly expressed in CD14+ cells as well as in mononuclear cells, so we 
analysed the expression of NLRC5 in the human monocytic cell line THP-1. Although, we could 
detect NLRC5 expression on mRNA level in these cells, the expression level was not upregulated 
after 6 h challenging with tumor necrosis factor (TNF), muramyl dipeptide (MDP), lipopolysac-
charide (LPS), phorbol 12-myristate 13-acetate (PMA) or Pam3CSK4 (activation of TLR1 and 
TLR2) in comparison to untreated control cells. All of the tested compounds induced inflamma-
tory responses in the cells, monitored by induction of IL-8 mRNA. However, no obvious 
changes in NLRC5 mRNA levels were observed (Figure 3.2 A). 
Similar to THP-1, epithelial HeLa cells also express detectable amounts of NLRC5 on 
mRNA level (Figure 3.1 B). Interestingly, expression was highly inducible in HeLa cells after 
stimulation with the dsRNA analog poly(I:C) in these cells, as detectable on mRNA level (Figure 
3.2 B) and on protein level (Figure 3.2 C). Moreover, whereas NLRC5 protein levels were at the 
detection limit in untreated HeLa cells, NLRC5 was robustly detectable after 24 h of poly(I:C) 
treatment (Figure 3.2 B). Furthermore, poly(I:C) failed to induce NLRC5 expression in the colon 
cell line CaCo2 (Figure 3.2 C). CaCo2 cells are known to be deficient of TLR3 signalling (Vijay-
Kumar et al., 2005; Alexopoulou et al., 2001) indicating that NLRC5 expression is induced by 
poly(I:C) in a TLR3-dependent manner (Figure 3.2 C). To substantiate that the induction of 
NLRC5 was mediated by the TLR3 pathway and not by other pattern recognition receptors acti-
vated by poly(I:C), siRNA-mediated knock-down of TLR3 and its downstream kinase TBK1 
were performed. This kinase is pivotal for the phosphorylation of IRF3 and thus expression of 
IFN- (Fitzgerald et al., 2003b). Knock-down of TBK1 was assured by Western blot and demon-
strated that NLRC5 induction upon poly(I:C) stimulation was mediated by the TLR3/TBK1 
pathway (Figure 3.2 D) . Thus, upregulation of NLRC5 by poly(I:C) is dependent on a functional 
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necrosis  factor  (TNF), 1 µM muramyl dipeptide  (MDP), 50 ng/ml  lipopolysaccharide  (LPS), 0.5 µM 
phorbol 12‐myristate 13‐acetate (PMA), or 100 ng/ml Pam3CSK. After 6 h of PAMP stimulation, RNA 




















A commonly used viral infection model in innate immunity is the single-stranded RNA 
containing Sendai Virus (SeV) model, which mainly leads to the activation of the RIG-I pathway, 
resulting in type I IFN expression. Based on the poly(I:C) dependent upregulation of NLRC5, we 
wondered, whether infection with SeV also induces NLRC5 expression. In line with the up-
regulation by poly(I:C), infection of cells with SeV led to an approximately 6-fold increase in 
NLRC5 mRNA levels in HeLa cells (Figure 3.2 E) and increased protein expression (Figure 3.2 
F). In contrast, as with poly(I:C), only a marginal (below 2-fold) induction of NLRC5 mRNA was 
obtained in THP-1 upon SeV infection (Figure 3.2 E). This showed that not only double-
stranded RNA but also single-stranded RNA or other viral signatures on SeV are able to induce 
NLRC5 expression. Furthermore, these experiments revealed that NLRC5 is differentially induc-
ible in different cell types. 
 
3.1.3 Innate Immune Signalling of NLRC5 
Most NLRs activate pro-inflammatory pathways such as NF-B or IL-1 processing (Kufer and 
Sansonetti, 2011). Since NLRC5 is mainly expressed by cells and tissues of the immune system 
and is highly inducible upon viral stimuli, we assumed a role for NLRC5 in one of these path-
ways. To test the ability of NLRC5 to activate a specific immune related pathway, we performed 
luciferase reporter assays in HEK293T cells (Zurek et al., 2011). This method is based on the fact, 
that overexpression of NLR proteins as for example NOD1 and NOD2 induces autoactivation, 
which is mediated by oligomerization of these proteins (Ogura et al., 2001; Inohara et al., 1999). 
We assumed that this property is shared by NLRC5. Indeed, overexpression of NLRC5 in 
HEK293T cells induced specific homooligomerization of NLRC5, whereas NLRC5 did not 
strongly interact with NLRP3 or NOD1. Thus, NLRC5 was also able to homooligomerize and 
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the reporter assay is also feasible for NLRC5 (Figure 3.3 A). Next, we tested the ability of 
NLRC5 to activate signalling pathways, which play important roles in immune signalling. Increas-
ing amounts of NLRC5 were expressed in HEK293T cells, and activation of inflammatory path-
ways was monitored using luciferase-reporter constructs. NF-B, IFN-, IRF3 (data not shown), 
IRF7, and ISRE reporter were tested, because they represent the most relevant innate immune 
pathways induced by viral and bacterial pathogens (Akira et al., 2006). 
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A)  FLAG‐tagged  NLRs  (NLRP3,  NLRC5  and  NOD1)  were  coexpressed  with  GFP‐tagged  NLRC5  in 













Although the tested reporter were significantly inducible by appropriate controls like 
TNF stimulation (for NF-B pathway induction) or SeV-infection/TBK1 overexpression (for 
IFN pathway induction), we were not able to activate any reporter by transfection of increasing 
amounts of NLRC5 (Figure 3.3 B). Expression of NLRC5 was further verified on protein level 
by western blot analysis in one representative experiment (Figure 3.3 C). To rule out the possibil-
ity that the failure of NLRC5 to induce inflammatory pathways was due to negative regulation by 
its LRRs, we repeated the experiments with a form of NLRC5 lacking the LRR domain (Isoform 
3; Figure 3.1 C). This protein formed a SDS stable dimer when overexpressed in HEK293T cells, 
likely being indicative for robust autoactivation (later depicted in figure 3.12 E). However, using 
this construct we obtained virtually the same result as with full-length NLRC5 (data not shown), 
suggesting that NLRC5 indeed is unable to activate the tested pathways upon overexpression in 
HEK293T cells. 
In conclusion, NLRC5 failed to induce the most prominent inflammatory pathways, sug-
gesting either, that an essential adaptor is lacking in HEK293T cells, or that NLRC5 is linked to 
signalling pathways that have not been tested here. 
To date, most of the already characterized NLR proteins are involved in innate immunity 
activation, although some NLRs also possess inhibitory function on innate immune pathways 
(reviewed in Kufer and Sansonetti, 2011). A very prominent example is the mitochondrial-located 
NLRX1, which was reported to inhibit antiviral immunity and NF-B signalling (Allen et al., 
2011; Xia et al., 2011). Taking this into consideration together with the fact, that NLRC5 is 
upregulated in response to viral infection, we wondered, whether NLRC5 is capable of inhibiting 
innate immune signalling pathways. To test our hypothesis, we transfected HEK293T cells with 
increasing amounts of NLRC5 and NF-B or IFN- reporter system. Additionally, cells were 
stimulated either with TNF to activate NF-B or IFN- was activated by overexpression of 
TBK1 or infection with SeV. Interestingly, overexpression of NLRC5 significantly impaired IFN-
 reporter activation in HEK293T cells without affecting NF-B, supporting a role for NLRC5 













































Effect  of  NLRC5  overexpression  on  activated  NF‐B  or  IFN‐  signalling  using  HEK293T‐based 







During our analysis, we observed that poly(I:C) and SeV induced NLRC5 expression (Figure 3.2). 
It is well established, that both poly(I:C) and SeV trigger type I IFN production, either by the 
TLR3 pathway (Alexopoulou et al., 2001) or by the intracellular RLR RIG-I (Kato et al., 2008). 
Furthermore, in our cell-based luciferase reporter assays, we detected an NLRC5-dependent in-
hibition of the IFN- promoter upon activation, either by overexpression of TBK1 or by SeV 
infection. Thus, we wanted to elucidate a possible role for NLRC5 in viral recognition. To ex-
plore, whether endogenous NLRC5 might have an impact on SeV-mediated responses, we set up 
a system to conduct siRNA-mediated gene knock-down in phorbol 12-myristate 13-acetate 
(PMA) differentiated THP-1 cells, because these cells showed the highest basal expression of 
NLRC5 (Figure 3.1). siRNA transfected cells were treated for 16 h with SeV and supernatant and 
cells were collected. Type I interferons are predominately induced by SeV in human cells (Hua et 
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al., 1996). We therefore measured secreted IFN- using a type I interferon-specific reporter cell 
line-based bioassay. NLRC5 knock-down reduced secretion of IFN- compared to mock treat-
ment with a nontargeting siRNA (control) (Figure 3.5 A). 
NLRC5 knock-down efficiency was controlled in cell lysates of the same experiment and showed 
robust reduction of NLRC5 protein levels (Figure 3.5 B). 
Moreover, we measured IFN- mRNA levels by quantitative RT-PCR simultaneously 
from the same experiments. In correlation with the bioassay data, IFN- mRNA levels were 
strongly induced by Sendai virus but showed a reduced induction in cells lacking NLRC5 (Figure 
3.5 C). Although the results were highly reproducible, variances in the siRNA efficiency between 
experiments impaired the generation of highly significant results. Importantly, however, reduc-
tion of the cytokine responses correlated with the knock-down efficiency of the two siRNA du-
plexes used, making it unlikely that the effect was due to off-target effects of the used siRNAs. 
To substantiate these results, we also assayed SeV-induced cytokines in THP-1 cells 
treated with the NLRC5 siRNA in comparison with mock treated cells. This showed a reduced 
release of RANTES (CCL5), MIP1 (CCL3), and IP-10, all cytokines well known to be induced 
by SeV in primary human cells (Matikainen et al., 2000; Hua et al., 1996) (Figure 3.5 D and E). 
The cytokine RANTES (CCL5) is highly inducible by type I IFN due to an IRF3-binding site in 
its promoter and plays an important role in viral recognition (Appay and Rowland-Jones, 2001; 
Song et al., 2000). In particular together with the cytokines MIP1 (CCL3) and IP-10, it has been 
reported, that these cytokines were strongly upregulated upon SeV infection (Matikainen et al., 
2000; Hua et al., 1996). Taken as a second read out, we performed an ELISA to detect RANTES 
release from NLRC5 knock-down cells upon SeV infection. Similar to type I IFN secretion (refer 
to Figure 3.5 A), also RANTES secretion was significantly reduced in NLRC5 knock-down cells 
(Figure 3.5 F). Moreover, RT-PCR confirmed reduced RANTES mRNA expression in cells lack-




































































































































































































After  incubation,  cells  were  stimulated  with  Sendai  virus  or  left  untreated  as  controls.  A  non‐
targeting siRNA was used as a control (siCTL). 
A) Type  I  interferon  release were assayed using a  type  I  interferon  secreted  alkaline phosphatase 
reporter cell line (HEK‐Blue™ IFN‐/ cells). The data are shown relative to control, with siCTL set to 
100 %. Depicted are mean ± SD (n=3). 




D) Analysis of  the cytokine secretion profile after SeV  infection of THP‐1 cells  treated with control 
siRNA  (siCTL)  or  the NLRC5  specific  siNLRC5_4  siRNA  using  a Western‐based  array. Densitometric 










To expand our results to primary cells, we used primary human dermal fibroblasts. First, 
we confirmed the expression of NLRC5 in these cells by RT-PCR. As observed for HeLa cells, 
treatment of human fibroblasts with 100 µg/ml poly(I:C) for 16 h led to significant induction of 
NLRC5 mRNA in cells derived from two different donors (male and female) (Figure 3.6 A). 
Next we conducted siRNA-mediated knock-down of NLRC5 in these cells for 72 h. Knock-
down of NLRC5 with two different siRNA duplexes led to reduced type I IFN and RANTES 
release both after poly(I:C) and after SeV treatment (Figure 3.6 B and C). As seen in THP-1 cells 
both siRNA duplexes reduced the responses to different levels, correlating to their knock-down 
efficiency as evaluated by RT-PCR from the same experiment (Figure 3.6 D).  
Although all donors showed slight variations in the response to poly(I:C) and SeV, the quality of 
the responses upon NLRC5 knock-down was comparable in all experiments. siNLRC5_4 was 
very potent in knocking down NLRC5 in donor 1 but less potent in donor 2, nevertheless, 
RANTES release was almost completely abolished in NLRC5 knock-down cells in response to 
both poly(I:C) and SeV. This led us to conclude that NLRC5 is needed for the efficient induction 
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C) RANTES  secretion  levels  from  the  same  supernatants used  in B after 16h of poly(I:C) or Sendai 














During the first part of this thesis, several reports analysed NLRC5 with conflicting results for 
many of the reported functions, including its ability to activate MHC class I transcription and its 
accurate function in immune signalling pathways still remains unresolved. To address these unre-
solved issues, we first tested the ability of our NLRC5 constructs to activate MHC class I pro-
moter regions in an HEK293T-based luciferase reporter assay (Zurek et al., 2011). For that pur-
pose, we cotransfected various amounts of an NLRC5 expression vector (1 to 10 ng plasmid) in 
HEK293T cells together with HLA class I A (HLA-A) and B (HLA-B) gene promoter reporter 
constructs (described in Gobin et al., 2001). Expression of NLRC5 significantly activated HLA-A 
and HLA-B luciferase reporter expression in this system (Figure 3.7 A). 
Moreover, overexpression of NLRC5 but not of NOD1 or NOD2 increased MHC class I pro-
tein levels in HEK293T cells (Figure 3.7 B). Thus, overexpression of NLRC5 significantly acti-































































































































Although, NLRC5 is referred to be a member of the Nodosome containing NLR proteins 
(Kufer and Sansonetti, 2011), it shows the closest homology within the NLR gene family to the 
MHC class II transcriptional activator (CIITA) in their NACHT and LRR domain (Istomin and 
Godzik, 2009; Proell et al., 2008). CIITA as an outstanding member of the NLR protein family 
does not play a role in pattern recognition, but its function is clearly defined as transcriptional 
activation (reviewed in Reith et al., 2005). This makes a functional analogy between these two 
NLR proteins plausible. Therefore, we compared the ability of NLRC5 and CIITA to activate 
HLA class II and I reporter gene constructs in HEK293T cells, respectively. Whereas NLRC5 
expression resulted in a significant and dose-dependent HLA class I induction, its effect on an 
HLA class II DRA promoter reporter construct was negligible. Vice versa, CIITA activated the 
HLA-DRA promoter strongly and showed a low, but reproducible activation of HLA-B pro-
moter (Figure 3.7 C). 
Overexpression of NLRC5 strongly activated MHC class I expression therefore knock-
down of endogenous NLRC5 in THP-1 should result in a decrease in MHC class I expression. 
Indeed, knock-down of NLRC5 in the myeloid macrophage-like cell line using siRNA robustly 
reduced mRNA levels of endogenous NLRC5 (Figure 3.8 A) and led to a decreased expression of 
HLA-B mRNA and HLA class I cell surface expression (Figure 3.8 B).  
Similar results were also obtained in HeLa cells (Figure 3.8 C). In all cases, transfection of control 
siRNA (siCTL) had no effect on NLRC5 or MHC class I gene expression as compared with un-
treated cells (Figure 3.8 A and C). 
We also analysed nontransformed primary human dermal fibroblasts, in which we in-
duced high levels of NLRC5 expression by treatment with poly(I:C) (refer to Figure 3.2 B). For 
both NLRC5-specific siRNA duplexes, knock-down of NLRC5 correlated with a reduction in 
endogenous HLA-B mRNA expression levels. Similar results were obtained in two different do-
nors (male and female), independently. Moreover, knock-down of NLRC5 also diminished HLA-
B expression triggered by SeV infection (Figure 3.8 D).  
Taken together, this strongly suggests that NLRC5 is involved in the control of constitu-




















































































































































Although, MHC class I expression is nearly ubiquitous on nucleated cells, strong differences can 
be found in expression levels between different cell types and tissues (van den Elsen et al., 2004; 
Burke and Ozato, 1989). In previous experiments, we could clearly point out, that the expression 
profile of NLRC5 also shows strong differences between cell types and tissues (Figure 3.1 A). 
Based on the previous findings, we asked whether NLRC5 levels correlate with basal 
HLA class I gene expression in human tissues. Comparison of HLA class I B mRNA expression 
levels with those of NLRC5 revealed a close correlation between the expression levels of both 
genes in tissues with non to very low (skeletal muscle and heart), intermediate (liver, kidney, pros-
tate, thymus, and colon), or high expression (resting CD8+ T cells). However, in some tissues, 
such as brain and lung, the expression levels were more disparate (Figure 3.9 A). These results are 
compatible with a positive role for NLRC5 in MHC class I gene expression but also suggest that, 
at least in certain tissues, other factors contribute to the overall expression levels. 
Several tissues and cell lines show very low to undetectable MHC class I expression (van 
den Elsen et al., 2004; Martin et al., 1997). One example is the murine melanoma cell line B16 and 
its various sublines (Krawczyk et al., 2008; Martin et al., 1997). In collaboration with Viktor 
Steimle and Galaxia Rodriguez, B16F10 cells were transfected with an empty vector or with vec-
tors expressing EGFP-NLRC5, EGFP-NLRC5 K234A or EGFP-CIITA. Analysis of transiently 
transfected cells showed that NLRC5 robustly induced MHC class I expression, whereas CIITA 
induced MHC class II expression. Expression of a Walker A mutant of NLRC5 (EGFP-NLRC5 
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After 2 weeks of selection with appropriate antibiotics, NLRC5-transfected B16F10 cells were 
sorted once with antibody and magnetic beads for MHC class I-positive cells, whereas CIITA-
transfected cells were enriched for MHC class II-positive cells (Figure 3.9 B and C). 
In parallel experiments, we were unable to enrich for MHC class I-positive or class II-positive 
cells in vector- or NLRC5-K234A–transfected cells, showing that B16F10 cells are negative or 
nearly negative for MHC class I and II  and that EGFP-NLRC5 K234A does not activate MHC 
class I expression (Figure 3.9 D). 
Stable expression of EGFP-NLRC5 induced endogenous MHC class I gene and protein expres-
sion levels very substantially in two independently transfected and selected cell populations (Fig. 
3.9 B3 and B4). Remarkably, MHC class I levels in the EGFP-positive cells were comparable to 
those found on freshly isolated murine splenic lymphocytes (Fig. 3.9 B2). The distinctive kink in 
the dot plots showing EGFP-NLRC5 expression on the x-axis and MHC class I (H-2Kb) on the 
y-axis (Figure 3.9 B3 and B4) suggests a threshold mechanism, where only a limited amount of 
NLRC5 expression is needed to fully activate endogenous MHC class I gene expression. EGFP-
CIITA also induced MHC class I expression in B16F10 cells, albeit less efficiently than NLRC5 
(Figure 3.10). As expected, MHC class II expression was strongly induced by EGFP-CIITA in 
the same cells (Figure 3.9 C5). The level of EGFP-CIITA expression is very low in these stable 
transfectants, because EGFP expression could not be detected (Figure 3.9 B5 and C5). However, 
we did detect EGFP expression readily in the same cells 2 D and 5 D (Figure 3.9 E) after trans-
fection, demonstrating the integrity of the construct (Figure 3.9 E). 
EGFP-NLRC5 expression had no effect on MHC class II expression in B16F10 cells (Figure 3.9 
C3 and C4). 
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These results show that endogenous NLRC5 and MHC class I mRNA expression levels 
are closely correlated in various cell lines and tissues and that NLRC5, on its own, is able to in-
duce high levels of endogenous MHC class I gene expression in B16F10 cells. 
 
 
3.2.3 NLRC5‐mediated MHC class  I expression  is dependent on nuclear shuttling and  the 
integral protein fold of NLRC5 
NLRC5 shares the typical tripartite structure of NLR proteins, consisting of an N-terminal effec-
tor domain, a central nucleotide-binding domain (also called NACHT domain) and a C-terminal 
leucine-rich repeat (LRR) domain. However, our knowledge of the contribution of these domains 
to the subcellular localization, nuclear trafficking and MHC class I activation of NLRC5 remains 
fragmentary. Therefore, we generated various NLRC5 deletion and point mutants (Figure 3.11 
D) and analysed their ability to shuttle to the nucleus by immunofluorescence analysis in HeLa 
cells, as well as their capacity to activate MHC class I transcription by HLA class I B promoter 
reporter assays in HeLa and HEK293T cells (Figure 3.11). 
Wildtype (wt) NLRC5 was localized predominantly in the cytoplasm, but inhibition of Crm1-
dependent nuclear export with LepB led to a strong nuclear accumulation of NLRC5 (Figure 3.11 
A). These experiments show that NLRC5 transits through the cell nucleus, which is in agreement 










































































































































































































0 1 5 10
NLRC5 wt [ng]
0 1 5 10
0 1 5 10
0 1 5 10
0 1 5 10









































epitope  tagged NLRC5  constructs  (schematic overview  in C)  for 24h. Cells were  fixed untreated or 

















The requirement of a functional ATPase domain in NLRC5 for subcellular localization and 
transport and the ability to activate MHC class I transcription were analysed by mutating the con-
served lysine residue (K234) in the predicted Walker A motif of NLRC5 to alanine (K234A) 
(Proell et al., 2008) . In contrast to wt NLRC5, NLRC5 K234A was localized exclusively in the 
cytoplasm, even after LepB treatment (Figure 3.11 A). In agreement with the cytoplasmic local-
ization, we found that NLRC5 K234A was unable to activate the HLA-B250 promoter in HeLa 
cells (Figure 3.11 B), which we also observed in HEK293T cells (Figure 3.11 C) and in B16F10 
cells (Figure 3.9 D). This suggests that nuclear shuttling of NLRC5 is essential for its activity on 
MHC class I gene expression. We previously showed that NLRC5 is expressed in various iso-
forms (refer to Figure 3.1). In this part of the study, we focused our attention on isoform 3, 
which lacks the entire LRR domain and is expressed in several human tissues (Figure 3.1 E). 
NLRC5 isoform 3 localized predominantly in the nucleus, even in the absence of LepB (Figure 
3.11 A), yet it completely failed to activate MHC class I transcription (Figure 3.11 B and C). This 
indicates that the C-terminal LRR domain is involved in nuclear export of NLRC5, as well as in 
transcriptional activation. CIITA contains, at its N-terminal end, a “classical” acidic activation 
domain that activates transcription in yeast when tethered to a promoter (Riley et al., 1995; Zhou 
and Glimcher, 1995). CIITA is expressed from four independent promoters, generating four 
isoforms (FI, FII, FIII, and FIV) (Muhlethaler-Mottet et al., 1997). Although CIITA-FII, FIII and 
FIV start at their N-terminal end with the acidic activation domain, CIITA-FI contains an addi-
tional domain N-terminal of the acidic domain, which has homology to a CARD domain. This 
CIITA-FI reported to contribute to MHC class II gene activation in vitro (Nickerson et al., 2001), 
whereas it seems to be dispensable in vivo (Zinzow-Kramer et al.). Although NLRC5 lacks an N-
terminal acidic activation domain found in CIITA, its N-terminal domain adopts a death domain 
fold. This death domain lacks obvious homology to the CARD and PYD found in other NLRs, 
including the CARD of CIITA-FI, or known transcriptional activation domains (refer to result 
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part 3.1.1 and figure 3.1 A). In contrast, the results shown above suggested that NLRC5 func-
tions as a transcriptional activator. Accordingly, we investigated whether the N-terminal NLRC5 
effector domain is necessary for MHC class I transcriptional activation. A truncated form of 
NLRC5, lacking the N-terminal part of the effector domain but still containing a recently identi-
fied nuclear localization signal at amino acid positions 122–134 (NLRC5DD NLS) (Meissner et 
al., 2010) was found in the nucleus in ~50% of HeLa cells in the absence of LepB. Nuclear local-
ization of this construct was increased by inhibiting nuclear export (Fig. 3.11 A); however, it was 
unable to activate the MHC class I promoter neither in HeLa nor in HEK293T cells (Figure 3.11 
B and C). These experiments show that the N-terminal death-fold domain, a functional ATPase 
domain, and the C-terminal LRR domain of NLRC5 are all required to induce MHC class I gene 
expression, whereas the requirements for nuclear shuttling are different. As expected from the 
previous experiments, the N-terminal death domain alone showed an exclusively nuclear localiza-
tion in the absence of LepB, whereas the LRR region alone was completely cytoplasmic due to 
the absence of a NLS domain, irrespective of the presence or absence of LepB (Fig. 3.11 A). Nei-
ther construct was able to activate MHC class I transcription in HeLa or HEK293T cells (Figure 
3.11 B and C). All constructs were expressed at comparable levels in HEK293T (Figure 3.11 E) 
and HeLa cells, showing that the differences in reporter gene activation reflect protein activity 
and not protein levels. 
The previous experiments were carried out by ectopic expression of epitope tagged pro-
tein constructs under the control of a strong viral promoter. Thus, overexpression can easily lead 
to saturation of transport pathways and may yield artifactual results. Therefore, we also analysed 
the subcellular localization of endogenous NLRC5 in HeLa cells by cytoplasmic and nuclear pro-
tein fractionation and subsequent western blotting. To obtain detectable amounts of NLRC5 
protein, cells were pretreated with poly(I:C) to induce NLRC5 expression (refer to Figure 3.1.6). 
This revealed a strong nuclear accumulation of endogenous NLRC5 after blocking of nuclear 
export by LepB, whereas NLRC5 was mainly cytoplasmic in untreated cells (Fig. 3. 12). Blotting 
for tubulin and lamin A/C demonstrated the absence of cross-contamination of cytoplasmic and 
nuclear fractions (Fig. 3.12, middle and lower panels). Of note, induction of NLRC5 expression 
by poly(I:C) treatment did not correlate with accumulation of NLRC5 in the nucleus. This is 
reminiscent of our observation that overexpressed NLRC5 strongly activated MHC class I gene 




































Taken together, these results show that NLRC5 shuttles through the nucleus and that 
MHC class I promoter activation is dependent on a functional ATPase domain and on the pres-
ence of both the death domain and LRR region of NLRC5, suggesting that the integral NLRC5 
fold is needed for subcellular transport and transactivation function. 
 
3.2.4 Nuclear–cytoplasmic shuttling of NLRC5 enhances MHC class I promoter activation 
In our previous experiments we found out that nuclear localization of NLRC5 is pivotal for acti-
vation of MHC class I signalling. In order to analyze the importance of nuclear shuttling in more 
detail, we asked whether forcing nuclear localization of NLRC5 would result in increased MHC 
class I promoter activation due to a faster and more efficient nuclear import. For that purpose, 
we generated NLRC5 constructs containing either a myc-epitope tag or a myc-epitope followed 
by a double SV40 NLS sequence at the N terminus (myc-2xNLS-NLRC5).  
As depicted in figure 3.13 A, this construct showed a predominantly nuclear localization 
(right image) without LepB treatment, which is in contrast to wt NLRC5, with a predominantly 
cytoplasmic localization in untreated cells (left image) and NLRC5 K234A with an unfailingly 












































































capacity to activate the HLA class I A and B promoters and did not show a dose-dependent in-





































B) HEK293T‐based  luciferase  reporter  assay  to  address  the  signalling  activity  of NLRC5  constructs 
from A.  Increasing amounts of NLRC5 constructs were  transiently  transfected  in  the presence of a 
HLA‐A230  or  HLA‐B250‐promoter‐driven  luciferase  constructs.  Luciferase  activity  was  normalized 
to‐galactosidase. The readout was performed in triplicates (Mean ± SD).  









Notably, this was not due to a change in protein stability or turnover, as assessed by Western 
blotting after blocking of protein synthesis using cycloheximide (Figure 3.13 D). Although we 
cannot formally exclude that the introduction of the NLS sequences affected the protein func-
tion, blocking nuclear export by LepB also led to decreased MHC class I gene activation in 
HEK293T cells by wildtype NLRC5 (Figure 3.13 C). 
This indicates that nuclear localization, as well as constant cytoplasmic/nuclear shuttling, is es-
sential for full NLRC5 activity. 
 
3.2.5  NLRC5‐mediated  MHC  class  I  promoter  activation  is  mediated  by  the  MHC  en‐
hanceosome 
To date, structure and activation of MHC class I promoter are well understood. Activation of 
MHC class I genes is dependent on a core promoter and upstream regulatory elements contain-
ing NF-B- and ISRE-binding elements and a regulatory region originally called site- (Gobin et 
al., 1997)This site- was shown to contain a region homologous to the S/X/Y composite cis-
acting crucial for MHC class II gene activation (Gobin et al., 1998b; Gobin et al., 1997; Martin et 
al., 1997). The MHC enhanceosome complex, and in particular the RFX complex, was shown to 
be required both for basal MHC class I expression (in absence of CIITA) and for CIITA-
dependent activated MHC class I expression (Gobin et al., 1997). Given the close homology of 
NLRC5 and CIITA, we anticipated that the site-/S/X/Y element is also involved in NLRC5-
mediated MHC class I promoter activation. In their previous study, Gobin and co-workers found 
a 5 nucleotide motif inside the X1 box element, which was crucial for both basal (CIITA-




CCAG t  cg c aTCGTGACGCG
X1             X2
"TCGCA"
HLA-B




















































10 105 51 10 0























1ng CIITA   +   CIITA




















1ng NLRC5  +   CIITA


























Therefore, we tested whether NLRC5 could activate an HLA class I B promoter reporter 
construct containing a mutated X1 box element (“TCGCA”; Figure 3.14 A). Testing the defec-
tive X1-Box HLA class I B250 “TCGCA” constructs in our HEK293T-based luciferase assay 
revealed an inability for overexpressed NLRC5 to activate this defective “TCGCA” construct, 
whereas NLRC5 robustly turned on the wt B250-luciferase construct in the same experiment 
(Figure 3.14 B; left panel). The parallel experiment with CIITA confirmed the results of Gobin 
and colleagues (Figure 3.14 B; right panel) (Gobin et al., 1998b). 
Interestingly, we found in this and similar experiments that the CARD-containing CIITA 
isoform I activated MHC class I expression more efficiently compared with isoform III (compare 
Figure 3.14, right panel with Figure 3.7 C, left panel and Figure 3.14 D). Taken together, these 
findings suggest that MHC class I activation by both NLRC5 and CIITA is dependent on a func-
tional X1 box.  
To date, the recruitment of CIITA to the MHC enhanceosome through multiple protein–
protein interactions with RFX5, RFXAP, RFX-ANK, CREB and NF-Y is pretty well understood 
(Figure 1.5) (DeSandro et al., 2000; Hake et al., 2000; Zhu et al., 2000; Scholl et al., 1997). Interest-
ingly, most of the interaction surfaces in CIITA were mapped to the NACHT and LRR regions 
(reviewed in Reith and Mach, 2001), since these regions show the highest sequence similarity 
between NLRC5 and CIITA (Istomin and Godzik, 2009; Proell et al., 2008). Thus, we reasoned 
that NLRC5 and CIITA might share, at least in part, similar interaction surfaces and, therefore, 
might be able to compete with each other for binding to the MHC enhanceosome. To test this 
hypothesis, we used a strongly dominant-negative N-terminally truncated CIITA mutant called 
CIITA-NLS-L335. CIITA-NLS-L335 is expressed at 30–50-fold higher levels compared with wt 
CIITA because of its greatly increased stability, and it displaces CIITA efficiently from the MHC 
class II promoter (Schnappauf et al., 2003; Masternak et al., 2000a; Bontron et al., 1997). In agree-
ment with Camacho-Carvajal and colleagues, overexpression of CIITA-NLS-L335 efficiently 
RESULTS 
79 
suppresses CIITA dependent MHC class II gene expression in a dose-dependent manner (Figure 
3.14 C, right panel and Camacho-Carvajal et al., 2004). 
Interestingly, we also observed a strong dose-dependent reduction in NLRC5-dependent 
MHC class I promoter activation when CIITA-NLS-L335 was coexpressed with NLRC5, sug-
gesting a competition between the two factors for the same binding sites (Figure 3.14 C, left 
panel). The previous experiments indicated that both NLRC5 and CIITA act via site-/S/X/Y 
and the MHC enhanceosome in the MHC class I promoters, thus we wanted to test for a possi-
ble cross-talk between these two factors. To elucidate this, we cotransfected a constant amount 
of NLRC5 with increasing amounts of CIITA and measured the activation of the HLA class I B 
reporter construct. As shown in Figure 3.14 D, we observed an additive effect of CIITA on 
NLRC5-dependent MHC class I expression. This further supports the hypothesis that NLRC5 
and CIITA occupy the same binding interface. 
Taken together, these results show that NLRC5 activates MHC class I gene expression 
via MHC enhanceosome binding to the site-/S/X/Y element and also suggest that NLRC5 









In paragraph 3.2, we figured out that MHC class I transcriptional activation by NLRC5 depends 
on a functional enhanceosome complex, similar to the activation of MHC class II by CIITA. Of 
note, similar results were obtained in a study from Meissner and co-workers (Meissner et al. 
2012c). Although, we provided evidence that NLRC5 mainly acts to drive MHC I expression 
whereas CIITA induces MHC II expression (Figure in 3.7 C), the underlying mechanism for this 
discrimination of MHC class I or MHC class II promoter sites by NLRC5 or CIITA remains 
largely elusive. To gain insight into the discrimination of MHC I and II promoters by NLRC5 
and CIITA, we generated a series of chimeric constructs containing combinations of different 
domains of NLRC5 and CIITA. First we started to swap the N-terminal effector domains leaving 
the NACHT-LRR C-terminus of CIITA or NLRC5 intact (Figure 3.15 A).  
Based on modelling of the structures and secondary structural database information 
(psipred v3.0) we defined the N-terminal domain of NLRC5 comprising amino acids 1 to 142 
RESULTS 
80 
(according to NP_115582). For CIITA, it was reported that deletion of the acidic domain (aa 1-
163) alone or the acidic and the proline/serine/threonine domain (aa 1-335) both resulted in 
dominant negative phenotypes (Camacho-Carvajal et al., 2004; Bontron et al., 1997; Chin et al., 





































































































































construct,  as  indicated  on  the  y  axis.  The  readout  was  performed  24  hours  after  transfection. 










We thus used two constructs of the N-terminal domain of CIITA; the acidic domain alone (aa 1-
163) and the acidic and P/S/T domain (aa 1-335) (according to NP_000237; refer to Krawczyk 
and Reith, 2006). These N-terminal domains were fused to the remaining C-terminal part of 
NLRC5 or CIITA as summarized in Figure 3.15 A. 
In a first set of experiments, we tested the ability of our chimeric fusion constructs to dif-
ferentially activate MHC class I or II promoters in HEK293T cells that do not express endoge-
nous NLRC5 (refer to figure 3.1) or CIITA (Hake et al., 2000), using luciferase gene-reporter as-
says. As expected, expression of 5 ng NLRC5 or 5 ng CIITA led to significant activation of the 
MHC I or MHC II reporter, respectively (Figure 3.15). NLRC5 with its effector domain (aa 1-
142) replaced by the CIITA N-terminal domain with (AD335-DD-NLRC5) or without the 
P/S/T-domain (AD163-DD-NLRC5) did neither significantly activate the HLA-B nor the 
HLA-DRA promoter (Figure 3.15 B). 
Interestingly, vice versa, after replacement of the N-terminal part of CIITA by the N-
terminal effector domain of NLRC5 (aa 1-142), we observed a potent activation of both the 
HLA-B250 and the HLA-DRA reporters (Figure 3.15). Activation of MHC class I and class II 
promoters by these chimeric constructs thereby was at least as potent as with NLRC5 or CIITA 
wildtype constructs. Moreover, even at concentrations of 0.5 ng plasmid per well, both constructs 
were sufficient for full blown reporter activation (Figure 3.15 C).  
Interestingly, the construct still harbouring the P/S/T-domain of CIITA (DD-AD163-
CIITA) showed a somewhat higher activity as compared to DD-AD335-CIITA in all assays 
(Figure 3.15 B and C). Comparable expression levels of the used constructs in the assays were 
verified by Western blot analysis (Figure 3.15 D). 
Of note, CIITA-L335, lacking the acidic domain and the P/S/T-domain was completely signal-
ling inactive (Figure 3.14 C) suggesting that MHC class I and II activation of this chimera was 
dependent on the effector domain of NLRC5. Nevertheless, the effector domain of NLRC5 is 
































In this work we established, that NLRC5 needs to shuttle to the nucleus in order to acti-
vate MHC class I gene expression (Figure 3.11 and Meissner et al., 2012c; Meissner et al., 2010) 
and similar results are reported for CIITA (Camacho-Carvajal et al., 2004; Hake et al., 2000). To 
address if lack of promoter activation of the AD335-DD-NLRC5 and AD163-DD-NLRC5 
constructs is a result of mislocalized protein, we expressed our collection of chimeras in HeLa 
cells and blocked nuclear export with 50 nM Leptomycin B (LepB) to force nuclear localization. 
In line with the results obtained in the reporter assays, AD335-DD-NLRC5 and AD163-DD-
NLRC5 were not detected inside the nucleus after LepB treatment (Figure 3.16, upper panels). In 
contrast, DD-AD163-CIITA and DD-AD335-CIITA were able to shuttle to the nucleus and 
showed a pronounced nuclear localization even without LepB treatment (Figure 3.16, lower pan-
els). The latter results fit well with the identification of a NLS in the effector domain of NLRC5 















Reasoning, that perturbed nuclear shuttling might be responsible for the lack of potent 
MHC activation of AD335-DD-NLRC5 and AD163-DD-NLRC5, we fused a double SV40 
NLS sequence at the N terminus of these constructs. However, we were not able to obtain nu-
clear shuttling of the NLS-tagged constructs, and accordingly observed no activation of either 

























A) HEK293T  cells were  transiently  transfected with  increasing  amounts of AD163‐DD‐NLRC5  and 
AD335‐DD‐NLRC5 constructs  in the presence of MHC class  I promoter  luciferase. The readout was 
performed  24  h  after  transfection.  HLA‐B250‐driven  luciferase  normalized  to  ‐galactosidase  is 
shown. The readout was performed in triplicates (Mean ± SD). 






















































































Finally, in order to validate the effect of our constructs on endogenous MHC class I and 
II protein expression, we expressed wildtype NLRC5, wildtype CIITA and our chimeric DD-
AD335-CIITA construct in HEK293T cells and analysed MHC class I and class II protein lev-
els in whole cell lysates by immunoblot analysis. As depicted in Figure 3.18, overexpression of 
wildtype NLRC5 and DD-AD335-CIITA strongly induced endogenous MHC class I protein 
expression, whereas the inactive K234A Walker A mutant of NLRC5 (NLRC5 K234A; Figure 
3.11 B and C) or CIITA failed to induce MHC class I expression (Figure 3.18). In agreement, 





























We wondered, whether the signalling activity of the NLRC5 effector domain can be 
maintained, when fused to other NLR protein backbones related to CIITA. To this end, we also 
generated a fusion protein of the NLRC5 effector domain to NOD1 lacking the CARD domain, 















































































NOD1 was chosen, since its function in pathogen recognition is already established and it has no 
transactivator activity (Kufer and Sansonetti, 2011; Kufer et al., 2006). Moreover, NOD1 is 
strongly activated by the peptidoglycan fragment TriDAP (Girardin et al., 2003b) and a working 
model for NOD1 was already proposed (Zurek et al., 2012a). Whereas NLRC5 potently activates 
HLA-B250-luciferase expression, NOD1 overexpression alone fails to induce HLA-B250-
luciferase expression (Figure 3.19 B). Moreover, overexpression of DD-DD-NOD1 did not 
activate HLA-B250-luciferase, neither in a control assay, nor with TriDAP induction (Figure 3.19 
B). Expression of DD-DD-NOD1 was verified by western blot analysis (Figure 3.19 C) and 
nuclear localization was controlled (Fig. 3.19 D). Although, the construct was well expressed and 
showed nuclear localization, no HLA-B250 promoter activation was detected with this chimeric 
NLR (Figure 3.19 B), strongly suggesting that particularities in the NACHT-LRR of CIITA are 
responsible for the transcriptional activity. 
 
3.3.2 Generation of LRR domain chimeric NLR proteins 
In case of NOD1 and NOD2, the leucine-rich-repeat domain has been reported to be essential 
to mediate activation of these NLRs and to drive NF-B activation by TriDAP or MDP, respec-
tively (Girardin et al., 2005; Tanabe et al., 2004). Furthermore, LRR swap experiments indicate 
that the sensing specificity of NOD1 and NOD2 can be interchanged by swap of their LRR do-
mains (Girardin et al., 2005). In CIITA, the LRR domain is strongly implicated in nuclear trans-
port and MHC class II activation (Ting and Trowsdale, 2002; Hake et al., 2000; Bontron et al., 
1997), whereas in NLRC5, the LRR domain plays a pivotal role in MHC class I activation and is 
involved in nuclear export. 
In order to test, if the LRR domains of NLRC5 and CIITA confer specificity for MHC 
class I versus MHC class II activation, we generated two LRR chimeric proteins, containing ei-
ther the NLRC5 N-terminus and the CIITA LRRs (NLRC5_562_LRR_762) or vice versa 
(CIITA_762_LRR_562) (Figure 3.20 A). 
In a first set of experiments, these LRR chimera constructs were tested in HEK293T-
based luciferase reporter assays. As depicted in Figure 3.20 B, neither the NLRC5_562_LRR_762 
nor the CIITA_762_LRR_562 construct did activate the MHC class I (upper left) or II (lower 
left) reporter, although the constructs were well expressed (Figure 3.20 C). 
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In indirect immunofluorescence experiments, NLRC5_562_LRR_762 was found to be 
able to localize to the nucleus even without LepB treatment, in agreement with the NLS in the 
N-terminal effector domain of NLRC5 (Meissner et al., 2010) and the lack of the NLRC5 LRR 
region, which plays a role in nuclear export (Figure 3.11). Vice versa, CIITA_762_LRR_562 was 
not able to shuttle to the nucleus, even after LepB treatment  
Taken together, although in principle, NLRC5_562_LRR_762 is able to shuttle to the nu-
cleus, it is not capable to activate either MHC class I or MHC class II promoter, showing that the 
used LRR domain of CIITA is not sufficient to compensate the function of the NLRC5 LRRs. In 
contrast, CIITA_762_LRR_562 is not able to shuttle to the nucleus, most likely, due to the lack 
of the CIITA LRR sequence, which is reported to be involved in nuclear shuttling (Camacho-


















B) HEK293T‐driven  luciferase assay with MHC class  I  (upper) or MHC class  II  (lower)  luciferase con‐
structs  in  the presence of NLRC5_562_CIITA_762 or CIITA_762_LRR_562  constructs.  Luciferase ex‐
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In the final part of the study, we analysed the specificity of the effector domain, the NACHT 
domain and the LRR domain of NLRC5 and CIITA in activation of MHC class I versus MHC 
class II expression. By generation of chimeric proteins, we observed, that the NLRC5 N-terminal 
effector domain fused to the CIITA C-terminus, including NACHT and LRR domain, com-
pletely restores MHC class I and, surprisingly, MHC class II activation. Although we could work 
out, that the NLRC5 effector domain induces MHC gene activation, the accurate underlying 









NLR proteins play pivotal roles as PRRs mediating detection of invading pathogens and trigger-
ing innate immune responses. In this study, we analysed the function of the NLR protein 
NLRC5. We started our enquiry with a detailed investigation of the expression pattern of NLRC5 
in several human tissues and cell lines. We observed highest expression of human NLRC5 
(hNLRC5) mRNA in hematopoietic cells, including monocytes, B cells and T cells. In line with 
that, immune related tissues, including spleen and lymph node showed higher expression than 
non-immune related tissue, including muscle tissue. Basal hNLRC5 expression in cell lines was 
restricted to myeloid (THP-1) and lymphoid (Jurkat) cells but was interestingly also found in the 
epithelial cell line HeLa (Figure 3.1). A similar expression analysis from Benko et al. supported 
our findings showing that hNLRC5 expression was mainly restricted to immune specific cells and 
tissues, including lymph node, lymphocytes and spleen (Benko et al., 2010). Nonetheless, contrary 
results concerning the mRNA levels of NLRC5 in some human tissues were reported by Kuenzel 
and co-workers (Kuenzel et al., 2010). Other NLR proteins as for example the well-established 
PRRs NOD1 and NOD2, which are closely related to NLRC5, were previously reported to be 
also expressed in APCs, as well as in hematopoietic cells (reviewed in Elinav et al., 2011), thus we 
hypothesized an immune related function for NLRC5 being likely. 
Six different isoforms of NLRC5 have been reported in databases (Figure 3.1). These iso-
forms differ from each other in their C-terminal LRR formation. For some NLR proteins, such 
as NOD1 and NOD2 a clear involvement of the LRR region in elicitor sensing was shown (Gi-
rardin et al., 2005; Tanabe et al., 2004), thus different LRR region compositions could enhance the 
variety of potential interacting elicitors or even change the conformation of the LRR region. We 
identified NLRC5 isoform 3 and isoform 4 and observed that isoform 3 is mainly expressed in 
CD8+ and CD4+, whereas isoform 4/5 is expressed at low levels in THP-1. Nevertheless, 
whether these NLRC5 mRNAs have biological relevance remains to be established. 
We found a poly(I:C)- and Sendai Virus (SeV)-dependent upregulation of hNLRC5 
mRNA and protein in non-hematopoietic cells, including HeLa cells and human primary dermal 
fibroblasts (hFibr). The induction by poly(I:C) was dependent on the TLR3/TBK1-signalling 
pathway, as verified in HeLa cells using siRNA (Figure 3.2). Recognition of SeV in human cells is 
independent of TLR3, but relies mainly on the cytoplasmic PRR RIG-I (Kato et al., 2006). Never-
theless, both TLR3 and RIG-I activation resulted in type I IFN induction in a TBK1-dependent 
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manner (refer to figure 1.1 and 1.3). Moreover, Kuenzel and colleagues reported increased 
hNLRC5 mRNA and protein levels upon IFN- treatment in HeLaS3 cells and THP-1 cells, but 
also in colon carcinoma cell lines, such as CaCo2 and HT29 (Kuenzel et al., 2010). Murine 
NLRC5 (mNLRC5) was found to be inducible by IFN- (Benko et al., 2010), poly(I:C) (Benko et 
al., 2010) and LPS (Benko et al., 2010; Cui et al., 2010). Also LPS was reported to augment 
NLRC5 expression, however this seems to be cell type specific (Benko et al., 2010; Cui et al., 
2010). Notably, we were not able to detect increased levels of hNLRC5 mRNA levels in THP-1 
cells after LPS stimulation, which was independently confirmed by Kuenzel et al. (Kuenzel et al., 
2010). A comprehensive analysis of mNLRC5 in BMDMs was provided by Staehli et al., clearly 
shows that poly(I:C)/TLR3-dependent and LPS/TLR4-dependent upregulation of mNLRC5 is 
mediated by type I IFN through STAT1 activation (Staehli et al., 2012) (also refer to figure 1.1and 
4.1). This is in line with our observations that hNLRC5 induction by poly(I:C) and SeV is a 
mechanism dependent on type I IFN release, rather than being directly dependent on TBK1 
(Figure 3.2). 
To elucidate a potential connection of hNLRC5 to innate immune signalling pathways, 
we further aimed to identify the signalling pathways linked to hNLRC5. Unlike other NLR pro-
teins such as NOD1, NOD2 and NLRP3, overexpression of NLRC5 did not activate the classical 
pro-inflammatory pathways including NF-B, MAPK or type I IFN (Figure 3.3). In contrast to 
our results, Kuenzel and colleagues reported that hNLRC5 activates ISRE- and INF- activating 
sequence (GAS)-containing promoters in HeLaS3 cells. They further provided evidence that this 
induction depends on dimerization of the N-terminal effector domain of NLRC5 (Kuenzel et al., 
2010). Since we used HEK293T cells, whereas Kuenzel and colleagues used HeLaS3 cells, a cell 
type specific activation of different pathways might explain this discrepancy. Even though, over-
expression of hNLRC5 did not result in activation of immune pathways, it inhibited TBK1- and 
SeV-mediated IFN- promoter activation (Figure 3.4). Noteworthy, also studies performed by 
Benko et al. and Cui et al. support an inhibitory function of NLRC5 in type I IFN signalling in 
similar experiments. Surprisingly, an inhibitory effect was also reported for NF-B signalling in 
cell-based reporter assays (Benko et al., 2010; Cui et al., 2010), which is in contrast to our observa-
tions in a similar experimental setup (Figure 3.4). Cui et al. further provided a model for the inhi-
bition of NF-B and IFN- by NLRC5. They reported an interaction of NLRC5 with IKK- 
and IKK-that inhibits their kinase activity. Additional interactions of NLRC5 with RIG-I and 
MDA5 were shown, blocking their signalling activity (Cui et al., 2010).  
However, in our hands, knock-down of NLRC5 decreased type I IFN expression and re-
lease in THP-1 cells upon SeV infection (Figure 3.5). Additional experiments in primary human 
dermal fibroblasts (hFibr), which are known to produce high levels of type I IFN (Sehgal and 
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Gupta, 1980; Sehgal et al., 1978), revealed an even more pronounced decrease of type I IFN ex-
pression upon poly(I:C) induction and SeV infection (Figure 3.6). In agreement with our findings, 
similar results were obtained by Kuenzel et al. using a CMV-based infection model. NLRC5 
knock-down resulted in a decrease of CMV-induced type I IFN release (Kuenzel et al., 2010). 
Although these results are in contrast to previous experiments using overexpressed NLRC5 in 
HEK293T cells (Figure 3.3), we assumed that overexpression in HEK293T cells resulted in titra-
tion of a factor, which is pivotal for IFN- induction. Such a scenario is very likely as shown by a 
recent study from Ling et al. that indicate that luciferase assays used for the analysis of NLR sig-
nalling are prone to such effects (Ling et al., 2012). Co-immunoprecipitation experiments per-
formed with TBK1, SINTBAD, TANK1, NAP1, IKK-, and IRF3, 7, and 5, as well as unbiased 
yeast two-hybrid screening of NLRC5 and its effector domain were conducted to address this 
observation in more detail (data not shown). Unfortunately, the results did not allow us to link 
NLRC5 to any known component of the type I IFN pathway yet, although as previously men-
tioned, Cui et al. were able to detect interactions between NLRC5 and IKK- and IKK-(Cui et 
al., 2010). 
Very recently, NLRC5-deficient mice were generated by different groups, which might 
help to clarify the implication of NLRC5 in immune signalling. Currently, five different full-body 
knock-out mice have been characterized (Biswas et al., 2012; Robbins et al., 2012; Staehli et al., 
2012; Tong et al., 2012; Yao et al., 2012; Kumar et al., 2011b). In line with their previous observa-
tion of hNLRC5 as an inhibitor of type I IFN and NF-B signalling (Cui et al., 2010), Tong and 
colleagues observed a strong increase in type I IFN and NF-B signalling upon TLR- and RIG-I 
activation in NLRC5-deficient mouse embryonic fibroblasts (MEFs) and peritoneal macrophages 
(PMMs) and to a lesser extent in bone marrow derived macrophages (BMDMs) (Tong et al., 
2012). Interestingly, no effect was observed in bone marrow-derived dendritic cells (BMDCs) 
deficient for NLRC5, which is in line with Kumar and co-workers, who were not able to detect 
altered type I IFN or NF-B signalling in their NLRC5-deficient mice (Kumar et al., 2011b). 
Thus, a cell type specific involvement of mNLRC5 in TLR and RIG-I signalling pathways seems 
to exist.  
Furthermore, a contribution of murine NLRC5 to inflammasome signalling was reported 
by Yao et al. (Yao et al., 2012), showing a moderate but significant effect on NLRP3 signalling but 
not on inflammasomes in general, although Kumar et al. did not observe a similar phenotype 
(Kumar et al., 2011b). Nonetheless, Kumar et al. provided evidence, that human NLRC5 is able to 
activate caspase-1, resulting in IL-1 maturation, which was supported by similar findings from 
Davis et al., reporting an involvement of human NLRC5 in inflammasome formation upon a 
broad variety of stimuli (Davis et al., 2010). 
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Still, fundamental differences in human and murine NLRC5 might account for the discrepancies 





NLR proteins are mainly responsible for cytosolic pathogen recognition, but additional functions 
have been reported for some NLR proteins. The most prominent example is the transcriptional 
activator CIITA, which was shown to control the expression of MHC class II molecules in vitro 
and in vivo (Reith et al., 2005). Alignment studies of the human NLR family performed for the 
nucleotide-binding domain and for the LRR region revealed a close homology between human 
CIITA (hCIITA) and human NLRC5 (hNLRC5) (Istomin and Godzik, 2009; Proell et al., 2008). 
Taking this into consideration, Meissner and co-workers analysed the capability of hNLRC5 to 
activate MHC molecule expression. They found out, that NLRC5 is able to induce the classical 
MHC class I molecules (HLA-A/B/C) as well as MHC class I presentation associated proteins 
(2-microglobulin, TAP1, MLP2) in HEK293T and in Jurkat cells. Whereas we and other groups 
reported a predominantly cytoplasmic localization of overexpressed NLRC5 under steady-state 
conditions, they could further show, that blocking of Crm1-dependent nuclear export by Lepto-
mycin B (LepB), resulted in nuclear accumulation of overexpressed hNLRC5 in HEK293T cells 
(Meissner et al., 2010). Benko et al. also detected nuclear shuttling of hNLRC5 in HeLa cells, 
however in contrast to Meissner et al. they observed enhanced basal and inducible MHC class I 
surface expression in murine RAW264.7 cells after lentiviral-mediated knock-down of mNLRC5 
(Benko et al., 2010). 
To clarify this discrepancy, we tested our hNLRC5 construct for the ability to activate 
MHC class I promoter in HEK293T-based luciferase reporter assays. In agreement with Meiss-
ner and colleagues, we were able to detect that NLRC5 induced both MHC class I promoter acti-
vation (Figure 3.7 A) as well as MHC class I expression on the protein level (Figure 3.7 B) in 
HEK293T cells, which originally display low basal MHC class I expression. In agreement with 
Martin and colleagues (Martin et al., 1997), Meissner and coworkers were able to detect high lev-
els of MHC class I after hCIITA overexpression in vitro (Meissner et al., 2010), whereas our 
CIITA construct failed to robustly activate the MHC class I promoter. Although we do not have 
an explanation for this contradiction, CIITA-deficient mice display normal MHC class I surface 
expression levels, debilitating a regulatory function of CIITA for MHC class I expression in vivo 
(Itoh-Lindstrom et al., 1999). In agreement with Meissner et al., hNLRC5 was not able to activate 
MHC class II expression in our studies (Figure 3.7 C) and also NLRC5-deficient mice do not 
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display altered MHC class II expression levels (Biswas et al., 2012; Staehli et al., 2012; Tong et al., 
2012; Yao et al., 2012). Knock-down experiments in THP-1 cells, basally expressing high levels of 
hNLRC5, or in poly(I:C)-induced HeLa cells supported a role for hNLRC5 in MHC class I ex-
pression, both on mRNA and on surface expression level (Figure 3.8). This finding was further 
expanded to primary human dermal fibroblasts, where HLA-B mRNA levels correlated with 
hNLRC5 expression levels. 
As previously mentioned, MHC class I molecules are expressed on almost all nucleated 
cells, although differences in their expression levels are detectable among different tissues (van 
den Elsen et al., 2004). Thus we compared the expression of HLA-B and hNLRC5 in several hu-
man tissues (Figure 3.9 A). As expected, we found a quite good correlation between HLA-B ex-
pression and hNLRC5 in several tissues, but also differences, for example lung tissue, indicating 
additional expression control mechanisms. We further analysed the contribution of hNLRC5 to 
MHC class I expression in the murine melanoma cell line B16F10, which is deficient for MHC 
class I expression. We could work out, that MHC class I expression was completely restored after 
stable transfection of B16F10 cells with hNLRC5 (Figure 3.9 B-E). Similar findings were also 
observed with MHC class I expression upon CIITA transfection in a study performed by Martin 
and colleagues (Martin et al., 1997), although we were not able to detect CIITA-dependent MHC 
class I expression. Of note, these results also show that human NLRC5 can functionally compen-
sate murine NLRC5 for its role in MHC class I gene expression. 
The involvement of NLRC5 in MHC class I regulation was further verified in mice by 
several independent studies (Biswas et al., 2012; Robbins et al., 2012; Staehli et al., 2012; Tong et 
al., 2012; Yao et al., 2012; Kumar et al., 2011b). Most of these studies reported reduced MHC 
class I levels in immune-related tissues and cells of NLRC5-deficient mice, including CD4+ T 
cells, CD8+ T cells and DCs, supporting our and Meissner’s in vitro findings (Meissner et al., 
2010). As a consequence of reduced MHC class I surface expression resulting in decreased anti-
gen presentation, Staehli and colleagues reported less efficient killing of NLRC5-deficient target 
cells by CD8+ T cells (Staehli et al., 2012). Nevertheless, MHC class I molecule expression does 
not completely rely on NLRC5 (also refer to figure 3.9 A), rather, it was shown to be inducible by 
IFN- in both control (NLRC5fl/fl) and NLRC5-deficient mice (Staehli et al., 2012), which was 
further confirmed by Biswas and colleagues (Biswas et al., 2012). This goes in line with our find-
ing, that certain tissues with low NLRC5 expression still show high amounts of MHC class I 
(Figure 3.9 A), supporting the presence of additional regulatory elements of MHC class I expres-
sion. 
MHC class I molecules are responsible for cytoplasmic antigen presentation to CD8+ T cells also 
in positive selection  in line with that, Staehli and colleagues detected slightly reduced CD8+ T 
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cell levels in the spleen of NLRC5-deficient mice. Evidence for in vivo relevance was given by 
Biswas and colleagues and Yao and colleagues, both independently describing severely reduced 
levels of CD8+ T cells and thus IFN- release in NLRC5-deficient mice after L. monocytogenes in-
fection. Conform to that, bacterial clearance was affected, indicated by increased bacterial burden 
in liver and spleen, clearly showing that NLRC5 in these studies is not a negative regulator of 
inflammatory responses (Biswas et al., 2012; Yao et al., 2012) 
Although Tong et al. detected decreased MHC class I surface expression in NLRC5-
deficient B and T cells, they concentrated on TLR signalling in these mice and were able to detect 
increased TLR responses in mice lacking NLRC5 (Tong et al., 2012), which goes in line with their 
first publication, revealing NLRC5 as a negative regulator of NF-B and type I IFN responses 
(Cui et al., 2010). Noteworthy, the phenotype was cell type specific and could not be observed in 
a similar study from Kumar et al. (Kumar et al., 2011b). Of note, the coherence of MHC class I 
expression and TLR signalling was addressed by a recent publication from Xu and co-workers 
(Xu et al., 2012). They proposed a working model, in which activation of TLRs leads to an MHC 
class I molecule-dependent activation of the phosphatase SHP2, which in term inhibits NF-B or 
type I IFN signalling (Xu et al., 2012). Although, this study needs further confirmation, these re-
sults provide a plausible explanation how NLRC5 might indirectly affect TLR and eventually also 
other immune signalling pathways, at least in selected cell types. 
During the first part of this study, we created deletion-constructs of NLRC5 (depicted in 
figure 3.11 D) to elucidate the mechanism of NLRC5 signalling in more detail. We tested HLA-
B-promoter activation as well as nuclear localization of these constructs. We found out, that 
NLRC5-dependent MHC class I activation relies on the complete domain structure of the pro-
tein (Figure 3.11), as well as on shuttling of the protein into the nucleus. Responsible for nuclear 
shuttling is an N-terminally located NLS (Meissner et al., 2010), as well as the NACHT ATPase 
activity (Figure 3.11; in terms of MHC class I activation also refer to Figure 3.9 D). Accordingly, 
NLRC5 constructs harbouring the N-terminal effector domain including NLRC5 wildtype, iso3 
and DD, were able to shuttle to the nucleus and accumulated after LepB stimulation (refer to 
figure 3.11). Interestingly, constructs lacking the LRR region showed nuclear localization even in 
the absence of LepB, including NLRC5 iso3 and DD. Thus the LRR region appears to be in-
volved in nuclear export. Although, NLRC5 and CIITA show close homology in their LRR re-
gion (Istomin and Godzik, 2009), differences in LRR function concerning subcellular localization 
are obvious. For CIITA it has been shown, that several structural features of the LRR region are 
important for nuclear import (Camacho-Carvajal et al., 2004; Harton et al., 2002; Hake et al., 
2000), whereas the LRR region of NLRC5 seems to be dispensable for nuclear import (Figure 
3.11). Additionally for CIITA, a functional nucleotide binding domain is crucial for MHC class II 
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activation. Interestingly, in contrast to other NLR proteins analysed so far, CIITA was reported 
to harbour a GTP-binding motif, rather than an ATP-binding motif (Chin et al., 1997). Although, 
the detailed role for GTP-binding in transcriptional activation of MHC class II by CIITA remains 
fragmentary (Bewry et al., 2007), it has been proposed, that reduced transactivator function in 
GTP-binding deficient CIITA constructs is rather a result of increased nuclear export, than of 
reduced transactivator function (Raval et al., 2003). Nevertheless, in contrast to NLRC5, disrup-
tion of the Walker A motif in CIITA abolished MHC transactivator activity without affecting 
nuclear shuttling (Bewry et al., 2007; Raval et al., 2003). A strong dominant negative effect was 
also observed for a CIITA construct lacking the acidic- and P/S/T-domain, indicating that this 
construct still was able to bind the enhanceosome, but was inable to recruit the transcription ma-
chinery (Camacho-Carvajal et al., 2004; Yun et al., 1997; Zhou et al., 1997). Unlike other NLR pro-
teins, the activity of CIITA completely relies on its transcriptional control, for example via IFN- 
induction of CIITA transcription. This means, CIITA is directly capable of MHC class II induc-
tion without any further stimuli, which is in contrast to NOD1, NOD2 or NLRP3 for example, 
which need a stimulus resulting in a conformational change for complete activation. Whether this 
is also the case for NLRC5 remains to be elucidated. To conclude, although the principle of ac-
tion seems to be comparable for CIITA and NLRC5, the domains involved in nuclear transport 
differ among both proteins, indicating further differences in the exact mechanism of MHC acti-
vation. 
Overexpression of proteins is prone to false positive results, in particular for studies on 
subcellular localization. To exclude false positive artefacts, we analysed the ability of endogenous 
NLRC5 in HeLa cells to shuttle to the nucleus. We boosted the expression of NLRC5 in HeLa 
cells using poly(I:C) and precipitated NLRC5 from the cytosolic and nuclear cell extracts. Using 
this technique we were able to detect endogenous NLRC5 inside the nucleus for the first time, a 
result that further supports ours and others findings regarding nuclear localization of NLRC5 
(Meissner et al., 2012c; Benko et al., 2010; Meissner et al., 2010). 
Both NLRC5- and CIITA-dependent MHC activation relies on nuclear shuttling. In con-
trast to NLRC5, which is mainly present in the cytoplasm in untreated cells (Figure 3.11), CIITA 
is predominantly localized inside the nucleus even under steady-state conditions (Hake et al., 
2000). Controversy, N-terminally NLS-tagged NLRC5, which is exclusively nuclear, showed a 
reduced MHC class I activation potential (Figure 3.13). Similar findings were reported by Meiss-
ner and colleagues, who obtained decreased MHC class I activation activity for nuclear forced 
NLRC5 (Meissner et al., 2012b). Although we cannot formally exclude that the added 2xNLS 
form SV40 disturbed the integrity of the N-terminal domain of NLRC5, we do not think that this 
is very likely, because N-terminal addition of the FLAG-epitope tag, the myc-epitope tag or even 
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EGFP did not appear to have an effect on the activity and transport behaviour of NLRC5 (Fig-
ure 3.9). Rather, we could also detect decreased MHC class I activation after 4h of LepB stimula-
tion in HEK293T-based luciferase assays (Figure 3.13 C). There are several possible explanations 
for this complex transport behaviour, which are not mutually exclusive. Transactivation potential 
might be dependent on cytoplasmic modifications of the proteins that are not carried out cor-
rectly if nuclear import is mediated via a “classical” importin-–dependent pathway. Noteworthy 
to mention here is the appearance of a double band in SDS-gel electrophoresis upon overexpres-
sion of NLRC5 or NLRC5-LRR, indicating of such modifications. It is possible that nuclear im-
port of NLRC5 depends on the interaction with protein partners in the cytoplasm. The involve-
ment of the LRR domain in this process makes this plausible, because LRR domains are best 
known as protein-interaction domains (Kobe and Kajava, 2001). Lastly, it is possible that nuclear 
export is somehow linked to the transactivation function of NLRC5 and CIITA. 
A working model for our findings concerning NLRC5 signalling in correlation with other 

















MHC class  I activation by NLRC5 requires nuclear presence as well as the complete  integral  fold of 
NLRC5. MHC  class  I  activation  by NLRC5  relies  on  the  enhanceosome  complex  and  is  further  en‐
hanced by cytoplasmic‐nuclear‐shuttling, most  likely due  to posttranslational modifications  (middle 
part).  
We  and Kuenzel  (Kuenzel  et al., 2010)  could  further provide evidence,  that NLRC5 plays a  role  in 



















































Working model for NLRC5 signalling










CIITA-dependent MHC class II activation relies on the enhanceosome complex, which binds 
mainly to the X1, X2-motif of the MHC class II promoter region (reviewed in Krawczyk and 
Reith, 2006; Reith et al., 2005). A similar region in the MHC class I promoter was shown to be 
important for enhanceosome-dependent MHC class I activation as well (Gobin et al., 1998b). 
Mutation of this X1, X2-motif completely abolished NLRC5-dependent MHC class I activation, 
demonstrating the dependency on the enhanceosome complex (Figure 3.14).  
This was further independently validated by Meissner et al., showing that NLRC5-
mediated MHC class I activation is dependent on the complete enhanceosome complex, consist-
ing of RFX-5, RFX-ANK and RFX-AP. Interestingly, Meissner and colleagues identified the S-
motif as an important motif for NLRC5-dependent MHC class I activation (refer to figure 1.5 
and figure 3.14), but dispensable for CIITA-dependent MHC class I activation in this study 
(Meissner et al., 2012c). To date, the role of the S-motif is not entirely clear, but an intact integrity 
of the S-motif is pivotal for the recruitment of CIITA to the MHC class II promoter in an en-
hanceosome-dependent manner (Muhlethaler-Mottet et al., 2004). Nonetheless, involvement of 
the S-motif in different regulatory mechanisms and specificity concerning the mode of action 
between NLRC5 and CIITA remain conceivable.  
Interaction between RFX-ANK and NLRC5 was reported by Meissner et al., by which binding to 
the enhanceosome complex is mediated. This interaction was depending on the ankyrin repeats 
of RFX-ANK, although this interaction has to be analysed in further detail (Meissner et al., 
2012c).  
Interestingly, whereas CIITA-FIII only marginally activated MHC class I promoter in our 
hands, the dendritic isoform FI showed a much stronger MHC class I activation (compare figure 
3.14 D or 3.14 B). To date, the function of the N-terminal CARD domain of CIITA-FI remains 
to be elucidated, however, a recent publication reported that CIITA-FI could not be linked to 
any critical function in antigen presentation and immune responses (Zinzow-Kramer et al., 2012). 
Thus, it remains unclear whether CIITA-FI can compensate for MHC class I expression in the 
absence of NLRC5.  
NLRC5 and CIITA both function as a transcriptional activator for MHC class I and II 
induction, respectively, which is mediated by the enhanceosome complex. To find out, which 
domain structure is important for specific recruitment of NLRC5 or CIITA, we generated chi-
meric constructs of NLRC5 and CIITA. In an earlier report from Girardin et al., fusion of the 
NOD2 LRR region to the NOD1 CARD and NACHT region resulted in a functional protein, 
which could be specifically induced by the NOD2 elicitor MDP, showing functionality of domain 
swapping between two related NLR proteins (Girardin et al., 2005). Based on these finding, we 
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generated constructs of NLRC5 containing only the effector domain (DD), or lacking the effec-
tor domain (DD) but including the NLS site, respectively. These constructs were fused to the 
CIITA C-terminus or N-terminus, respectively (refer to figure 3.15 A). CIITA AD (AD163-
DD-NLRC5) or AD and P/S/T (AD335-DD-NLRC5) domains fused to NLRC5-NACHT-
LRR region are completely signalling inactive in HEK293T-based luciferase reporter assays. 
Camacho-Carvajal and co-workers identified a CIITA-mutant lacking AD and P/S/T (aa 1 to 
335; termed CIITA-L335) harbouring a strong dominant negative effect on CIITA signalling 
when fused to an NLS (CIITA-NLS-L335) (Camacho-Carvajal et al., 2004). Unexpectedly, we 
were able to restore MHC class II activation of the CIITA-L335 constructs as well as MHC class 
I activation potential by N-terminal fusing of the NLRC5 death domain-fold domain to this con-
struct (DD-AD335-CIITA) (Figure 3.15 B; right). To date, the exact function of the P/S/T 
domain remains unresolved (Boss and Jensen, 2003) and it was also dispensable for MHC activa-
tion in our constructs, since both constructs either harbouring the P/S/T (DD-AD163-CIITA) 
or lacking the P/S/T (DD-AD335-CIITA) offered similar signalling activities. These findings 
were further verified in HEK293T cells with comparable induction for endogenous MHC class I 
and class II expression levels (Figure 3.18). 
Similar to wildtype NLRC5 and CIITA, both DD-AD163-CIITA and DD-AD335-
CIITA were able to shuttle to the nucleus, whereas AD163-DD-NLRC5 and AD335-DD-
NLRC5 remained entirely cytoplasmic, most likely due to the lack of the N-terminal NLS of 
NLRC5, which promotes nuclear import. However, nuclear accumulation could not be achieved 
for AD163-DD-NLRC5 and AD335-DD-NLRC5 by fusion to a double SV40 NLS, although 
small background activation of MHC class I promoter luciferase remained detectable (Figure 
3.17).  
The molecular mechanism involving MHC class II activation by CIITA has been analysed 
in great detail and it has been established, that enhanceosome-binding of CIITA is mediated by 
the LRR and NACHT region (also refer to the dominant negative function of CIITA-L335), 
whereas the N-terminal transcription activation domain (AD) mediates transcription machinery 
recruitment (reviewed in Krawczyk and Reith, 2006; Ting and Trowsdale, 2002; Reith and Mach, 
2001). The fact, that DD-AD163-CIITA and DD-AD335-CIITA activate both MHC class I 
and MHC class II expression, even without the AD of CIITA leads to the conclusion, that the 
effector domain of NLRC5 is sufficient to recruit components of the transcription machinery, 
which drive both MHC class I and MHC class II transcription. To maintain specificity for MHC 
class I transcription by NLRC5, recruitment of additional regulatory factors seems likely. Initial 
experiments from Meissner et al. show, that the S-box motif is important for NLRC5-mediated 
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MHC class I induction, but not for CIITA-mediated MHC class I induction in luciferase reporter 
assays (Meissner et al., 2012b).  
The effector domain of NLRC5 completely restores the activity of CIITA-L335 to induce 
MHC class II expression and also activates MHC class I expression (Figure 3.15). To analyse, 
whether the effector domain of NLRC5 is also capable of MHC class I activation fused onto the 
NACHT-LRR region of other related NLR proteins, we fused the effector domain of NLRC5 to 
the NACHT-LRR region of the PRR NOD1, which itself is neither able to shuttle to the nucleus, 
nor activate MHC expression (Zurek et al., 2012b and Figure 3.19). Fusion of the effector domain 
to the NOD1-NACHT-LRR region benefits nuclear import, most likely due to the N-terminal 
NLS of NLRC5. However, nuclear DD-DD-NOD1 did not maintain MHC class I promoter 
activation in our experimental setup, most likely because of the inability of the NOD1 NACHT-
LRR region to interact with components of the enhanceosome complexes. To conclude, al-
though the NLRC5 effector domain is pivotal for MHC class I activation and also capable of 
MHC class II activation to a certain extend in a NLRC5-CIITA-chimeric protein, most likely due 
to beneficial recruitment of additional factors by the NACHT-LRR region of CIITA, it is not 
sufficient to trigger MHC expression, when these factors are missing. 
Finally, we addressed the contribution of the LRR region of NLRC5 and CIITA to MHC 
promoter activation. Distinct analyses of the LRR of CIITA revealed pivotal functions in nuclear 
shuttling and activation of MHC class II promoter (Camacho-Carvajal et al., 2004; Hake et al., 
2000). Although detailed analyses are missing so far for NLRC5, increase in nuclear accumulation 
of NLRC5 constructs lacking the LRR was observed. Thus a contribution of the LRR of NLRC5 
in nuclear export seems conceivable. Nevertheless, fusion of NLRC5 N-terminus and CIITA-
LRR as well as CIITA-N-terminus and NLRC5-LRR neither activated MHC class I promoter 




The results obtained in this thesis cover two different roles for the NLR protein NLRC5. On the 
one hand, we show that NLRC5 is inducible upon TLR3 and RIG-I stimulation, both triggering 
different pathways, resulting in type I IFN production. Interestingly, also NLRC5 itself contrib-
utes to type I IFN expression upon TLR3 and RIG-I stimulation, verified by knock-down ex-
periments in the lymphoid cell line THP-1 as well as in human primary dermal fibroblasts 
(hFibr). On the other hand, we show that NLRC5 can shuttle to the nucleus and activates MHC 
class I gene expression. Moreover, we provided evidence, that the mechanism of MHC class I 
activation is similar to MHC class II activation, which is mediated by the closely related NLR 
protein CIITA. We identified the enhanceosome complex as crucial component of NLRC5-
dependent MHC class I activation. Furthermore, we obtained first insights into the contribution 
of the N-terminal effector domain to trigger MHC class I activation as well as in exceptional cir-
cumstances also MHC class II activation.  
MHC class I surface expression plays an important role in clearance of cytoplasmic 
pathogens, for example viruses and bacteria, since pathogen-derived cytoplasmic antigens are 
presented to the cell surface via the MHC class I pathway (refer to figure 1.4). In the present 
work, we could demonstrate that NLRC5 is upregulated upon different viral PAMPs, including 
poly(I:C) and SeV resulting in increased MHC class I levels. In particular after viral infections, the 
host organism profits from enhanced antigen presentation in infected cells, resulting in cytotoxic 
T cell mediated killing and restriction of local infections. Interestingly, NLRC5 itself contributes 
to antiviral immunity by maintaining type I IFN responses in human. Thus, due to its bifurcate 
function, NLRC5 is a promising candidate for antiviral immune therapy. 
Importantly to mention, cancer therapy greatly profits from a better understanding of 
MHC class I regulation. It is known for a long time, that many tumors show reduced or impaired 
MHC class I surface expression, which provides a mechanism for tumors to escape immunosur-
veillance, although the detailed mechanism remains to be elucidated (Reinis, 2011). Moreover, 
cancer database records link the upregulation of classical MHC class I surface molecules (HLA-
A/B/C) in cancer cell lines also to upregulation of NLRC5 protein 
(http://www.broadinstitute.org/ccle/home). 
Although the detailed mechanism of NLRC5 in MHC class I regulation still remains to be 
elucidated, we identified an NLRC5-CIITA chimeric protein, which potently activates MHC class 
I and MHC class II expression and could demonstrate the contribution of the N-terminal effec-
tor domain in this process. The use of this chimeric protein can further lead to a better under-
standing of the discrimination between MHC class I and MHC class II transcriptional regulation.  
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The identification of NLRC5 as the MHC class I transactivator as well as our identifica-
tion of an NLRC5-CIITA-chimeric protein that activates both MHC class I and class II expres-
sion further contributes to the understanding of MHC regulation and to the development of new 
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Nucleotide-binding domain, leucine-rich repeat (NLR)-containing proteins play important roles 
in the innate immune system as intracellular pattern recognition receptors. The most prominent 
members, NOD1, NOD2 and NLRP3 have been extensively shown to trigger NF-B activation 
or IL-1/IL-18 processing upon pathogen infection, respectively. Nonetheless, other functions 
beyond pathogen recognition have also been reported for some NLR proteins. 
Here we report the first characterization of the human NLR protein NLRC5. NLRC5 lacks the 
typical N-terminal CARD or PYRIN domain of most NLR proteins, but harbours a death do-
main fold effector domain with yet unknown function. Interestingly, NACHT and LRR domain 
alignments reveal close homology to the MHC class II transcriptional activator (CIITA), which is 
responsible for the transcriptional induction of MHC class II molecules, and moderate homology 
to NOD1 and NOD2. 
In the first part of this study, we addressed the expression and regulation of NLRC5 in 
different tissues and cell lines. We detected NLRC5 expression primarily in cells and tissues of 
the immune system, including CD4+ and CD8+ T cells and spleen, lymph node and bone mar-
row. Furthermore, we were able to induce a TLR3-dependent NLRC5 induction upon stimula-
tion with the dsRNA-mimic poly(I:C) as well as an TLR3-independent NLRC5 induction using a 
Sendai Virus (SeV)-based infection model. In line with that, we revealed a role for NLRC5 in 
type I interferon (IFN) response against RNA viruses. Moreover, we adapted an infection model 
of primary human dermal fibroblasts (hFibr) with Sendai Virus (SeV), depicting a distinct role for 
NLRC5 in anti-viral immune processes.  
In the second part, we investigated the role of NLRC5 in MHC class I promoter activa-
tion. Similar to MHC class II promoter activation by the non-DNA binding coactivator CIITA, 
we were able to obtain a clear role for NLRC5 in MHC class I expression and identified the do-
mains, which are important for nuclear translocation and MHC class I promoter activation. We 
further analysed the involvement of a DNA-binding complex, the so-called enhanceosome, in 
NLRC5-dependent MHC class I expression, which is pivotal for CIITA-dependent MHC class II 
expression.  
 Finally, we generated NLRC5-CIITA-chimeric proteins to decipher the NLRC5-
dependent MHC class I and CIITA-dependent class II activation in more detail. Domain swap-
ping of the N-terminal effector domains revealed, that the NLRC5 N-terminal effector domain 
fused to the C-terminus of CIITA is sufficient to activate both MHC class I and MHC class II 
expression.  
Taken together, in this study we identified a role for NLRC5 in anti-viral immune responses and 




Mitglieder der intrazellulären NLR Proteinfamilie spielen als Mustererkennungs-Rezeptoren 
(PRRs) entscheidende Rollen im angeborenen Immunsystem. Zu den bekanntesten NLR Protei-
nen gehören NOD1, NOD2 und NLRP3, welche bereits ausgiebig im Hinblick auf ihre Fähigkeit 
NF-B und IL-1/IL-18 Signalwege auszulösen untersucht wurden. Neben diesen wurden eben-
falls rezeptorunabhängige Funktionen für einige NLR Proteine in der Literatur beschrieben. 
Im Rahmen dieser Arbeit wurde eine erste Charakterisierung des menschlichen NLR Proteins 
NLRC5 durchgeführt. Zwar fehlt NLRC5 die typische N-terminale CARD- oder PYRIN-
Domäne der meisten NLR Proteine, dennoch besitzt es eine todesdomänenartige (death domain 
fold) Struktur mit bislang ungeklärter Funktion. Interessanterweise zeigen die nukleotidbindende 
Domäne und die leuzinreiche Domäne eine starke Homologie zum MHC Klasse II Aktivator 
CIITA, welcher für die transkriptionelle Induktion von MHC Klasse II Molekülen verantwortlich 
ist, als auch eine mittelmäßige Homologie zu NOD1 und NOD2. 
 Im ersten Teil dieser Arbeit wurde die Expression und Regulation von NLRC5 in ver-
schiedenen Geweben und Zelltypen untersucht. NLRC5 Expression war hauptsächlich in Zellen 
und Geweben des Immunsystems, wie zum Beispiel in CD4-positiven und CD8-positiven T-
Zellen, sowie in Milz, Lymphknoten und Knochenmark, nachweisbar. Außerdem konnte die 
Expression von NLRC5 durch Stimulation des Toll-ähnlichen Rezeptors 3 (TLR3) mit dem dop-
pelsträngigen RNA Analogon poly(I:C), sowie TLR3-unabhängig durch Sendaivirusinfektion 
induziert werden. Zusätzlich konnte eine Funktion von NLRC5 in RNA-virusabhängige Typ I 
Interferoninduktion aufgedeckt werden, welche zusätzlich in einem Sendaivirusinfektionsmodel 
von menschlichen primären Fibroblasten nachgewiesen werden konnte. 
 Im zweiten Teil der Arbeit wurde die Fähigkeit von NLRC5 den MHC Klasse I Promotor 
zu aktivieren untersucht. Vergleichbar mit der CIITA-induzierten MHC Klasse II Promoterakti-
vierung konnte eine klare Beteiligung von NLRC5 an der MHC Klasse I Expression nachgewie-
sen werden, sowie die Bedeutung des nukleären Transports herausgearbeitet werden. Außerdem 
wurde der Einfluss eines DNA-bindenden Multiproteinkomplexes namens Enhanceosome, wel-
cher in der CIITA-abhängigen MHC Klasse II Expression unabdingbar ist, ebenfalls in der 
NLRC5-abhängigen MHC Klasse I Expression nachgewiesen. 
 Zum Schluss wurden NLRC5-CIITA-Chimären generiert, um die NLRC5-abhängige 
MHC Klasse I und die CIITA-abhängige MHC Klasse II Expression genauer zu untersuchen. 
Ein Domänenaustausch der N-terminalen Effektordomänen hat ergeben, dass die NLRC5 Effek-
tordomäne zusammen mit der nukleotidbindenden Domäne und der leuzinreichen Domäne von 




In dieser Arbeit konnte nicht nur eine Funktion von NLRC5 in der antiviralen Immun-
abwehr identifiziert werden, sondern auch ein Beitrag zum Verständnis von NLRC5-abhängiger 
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